 
IGHID 12021 – UNC CCP RCT_18 November 2020_v3.1  i IGHID 12021 - A RANDOMIZED, PHASE II STUDY 
COMPARING THE EFFICACY AND SAFETY OF STANDARD 
VERSUS HIGH -TITER  ANTI -SARS -COV -2 NEUTRALIZING 
ANTIBODY PLASMA IN HOSPITALIZED PATIENTS WITH 
COVID -19 
Principal Investigator: Luther Bartelt , MD  
Version 3.1 
18 November  2020  
IND Number:  IND 22282 
Study Registry ID: [REMOVED]  
 
Funding Source: University of North Carolina at Chapel Hill, School of Medicine  
 
 
 
 
  
 
  
 
  
 
 
IGHID 12021 – UNC CCP RCT_18 November 2020_v3.1  ii IGHID 12021  - A RANDOMIZED, PHASE II STUDY 
COMPARING THE EFFICACY AND SAFETY OF STANDARD 
VERSUS HIGH -TITER ANTI- SARS -COV -2 NEUTRALIZING 
ANTIBODY PLASMA IN HOSPITALIZED PATIENTS WITH 
COVID -19 
 
SIGNATURE PAGE  
 
I will conduct the study in accordance with the provisions of this protocol and all applicable protocol -related 
documents. I agree to conduct this study in compliance with United States (US) Health and Human Service 
regulations (45 CFR 46); applicable U.S.  Food and Drug Administration regulations; standards of the International 
Conference on Harmonization Guideline for Good Clinical Practice (E6); Institutional Review Board/Ethics 
Committee determinations; all applicable in -country, state, and local laws and regulations; and other applicable 
requirements (e.g., US National Institutes of Health, Division of AIDS) and institutional policies.  
  
Investigator of Record: _______________________________________________  
Print/Type  
  Signed: ______________________ _____________ Date: ____________________  
   Title: _____________________________________  
  
  
IGHID 12021 – UNC CCP RCT 18 November -2020_v3.1  ii Table of Contents  
PROTOCOL TEAM  .................................................................................................................................................... 1  
STATEMENT OF COMPLIANCE ............................................................................................................................. 2  
1 PROTOCOL SUMMARY  .............................................................................................................................. 3  
1.1 Synopsis  ............................................................................................................................................... 3  
1.2 Schema  ................................................................................................................................................. 6  
1.3 Schedule of Activities (SoA)  .............................................................................................................. 7  
2 INTRODUCTION  ............................................................................................................................................ 8  
2.1 Study Rationale  ................................................................................................................................... 8  
2.2 Background  .......................................................................................................................................... 8  
2.3 Risk/Benefit Assessment  ................................................................................................................. 11 
2.3.1  Known Potential Risks  .................................................................................................. 11 
2.3.2  Known Potential Benefits .............................................................................................. 13 
2.3.3  Assessment of Potential Risks and Benefits  ............................................................. 14 
3 OBJECTIVES AND ENDPOINTS  .............................................................................................................. 14 
4 STUDY DESIGN  .......................................................................................................................................... 16 
4.1 Overall Design  ................................................................................................................................... 16 
4.2 Scientific  Rationale for Study Design  ............................................................................................. 16 
4.3 Justification for Dose  ........................................................................................................................ 17 
4.4 End of Study Definition  ..................................................................................................................... 17 
5 STUDY POPULATION  ................................................................................................................................ 17 
5.1 Inclusion Criteria  ................................................................................................................................ 17 
5.2 Exclusion Criteria  .............................................................................................................................. 18 
5.3 Strategies for Recruitment and Retention  ..................................................................................... 18 
6 STUDY INTERVENTION  ............................................................................................................................ 18 
6.1 Study Intervention(s) Administration  .............................................................................................. 18 
6.1.1  Study Intervention Description  ..................................................................................... 18 
6.1.2  Dosing and Administration  ........................................................................................... 18 
6.2 PREPARATION/Handling/Storage/Accountability  ....................................................................... 19 
6.3 measures to minimize bias  .............................................................................................................. 19 
7 STUDY INTERVENTION DISCONTINUATION  PARTICIPANT               
DISCONTINUATION/WITHDRAWAL  ................................................................................................................... 19 
7.1 Discontinuation of Study  ................................................................................................................. 20 
7.2 P articipation Termination  .................................................................................................................. 20 
7.3 Participant Discontinuation/Withdrawal from the Study  ............................................................... 20 
7.4 Lost to Follow -Up .............................................................................................................................. 21 
8 Study Assessments and Procedures  ........................................................................................................ 21 
Safety and Other Assessments  .......................................................................................................................... 21 
8.1 Efficacy Assessments ....................................................................................................................... 21 
8.2 safety and other assessments  ......................................................................................................... 24 
8.3 Adverse Events and Serious Adverse Events  .............................................................................. 25 
8.3.1  Definition of Adverse Events (AE)  ............................................................................... 25 
8.3.2  Definition of Serious Adverse Events (SAE)  .............................................................. 25 
8.3.3  Classification of an Adverse Event  ............................................................................. 25 
8.3.4  Time Period and Frequency for Event Assessment and Follow -Up ...................... 26 
8.3.5  Adverse Event Reporting .............................................................................................. 27 
8.3.6 Serious Adverse Event Reporting  ............................................................................... 27 
8.3.7  Reporting Events to Participants  ................................................................................. 28 
  
IGHID 12021 – UNC CCP RCT 18 November -2020_v3.1  iii 8.4 New safety information  ..................................................................................................................... 28 
8.4.1  Definition of new safety information (NSI)  .................................................................. 28 
8.4.2  New Safety Information Reporting  .............................................................................. 28 
8.4.3  Reporting New safety Information to Participants ..................................................... 29 
9 STATISTICAL CONSIDERATIONS  .......................................................................................................... 29 
9.1 Statistical Hypotheses  ...................................................................................................................... 29 
9.2 Sample Size Determination  ............................................................................................................. 29 
9.3 Populations for Analyses  .................................................................................................................. 29 
9.4 Statistical Analyses  ........................................................................................................................... 29 
9.4.1  SAfety analyses  ............................................................................................................. 29 
9.4.2  General Approach  ......................................................................................................... 30 
9.4.3  Analysis of the Primary Efficacy Endpoint(s)  ............................................................. 31 
9.4.4  Sub-Group Analyses  ..................................................................................................... 31 
9.4.5  Exploratory Analyses  .................................................................................................... 31 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  .............................. 33 
10.1  Regulatory, Ethical, and Study Oversight Considerations  .......................................................... 33 
10.1.1  Informed Consent Process  ........................................................................................... 33 
10.1.2  Study Discontinuation and Closure  ............................................................................. 33 
10.1.3  Confidentiality and Privacy  ........................................................................................... 34 
10.1.4  Future Use of Stored Specimens and Data  ............................................................... 35 
10.1.5  Key Roles and Study Governance  .............................................................................. 35 
10.1.6  Safety Oversight  ............................................................................................................ 35 
10.1.7  Clinical Monitoring  ......................................................................................................... 36 
10.1.8  Quality Assurance and Quality Control  ...................................................................... 36 
10.1.9  Data Handling and Record Keeping  ........................................................................... 37 
10.1.10  Protocol Deviations  ....................................................................................................... 37 
10.1.11  Publication and Data Sharing Policy  ........................................................................... 38 
10.1.12  Conflict of Interest Policy  .............................................................................................. 38 
10.2  Abbreviations  ..................................................................................................................................... 38 
10.3  Protocol Amendment History  ........................................................................................................... 40 
11 REFERENCES  ............................................................................................................................................. 42 
 
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   1 PROTOCOL TEAM  
Principal Investigator  
Luther A. Bartelt, MD  
Assistant Professor of Medicine, Department of 
Medicine  
University of North Carolina at Chapel Hill Division of Infectious Diseases  
120 Mason Farm Road, 7314 Medical Biomedical Research Building, C ampus Box (CB) 7032 
Chapel Hill, NC 27599 -7032 
Phone: (919) 966- 6152 
E-mail: luther_bartelt@med.unc.edu  
 Co-Principal Investigator  
David M. Margolis, MD  
Professor of Medicine, Microbiology & Immunology  
University of North Carolina at Chapel Hill Division of Infectious Diseases  
120 Mason Farm Road, 2060 Genetic Medicine Building, CB 7042  
Chapel Hill, NC 27599 -7042 
Phone: (919) 966- 6388 
E-mail: dmargo@med.unc.edu 
 
Co-Investigator  
David van  Duin, MD PhD  
Associate Professor, Department of Medicine  
University of North Carolina at Chapel Hill Division of Infectious Diseases  
120 Mason Farm Road, Bioinformatics, CB 7030  
Chapel Hill, NC 27599 -7032 
E-mail: david_vanduin@med.unc.edu  
 Statistician  
Sonia Napravnik, PhD  
Associate Professor of Medicine, Epidemiology  
University of North Carolina at Chapel Hill Division of Infectious Diseases  
130 Mason Farm Road, 2nd Floor Bioinformatics 
Building, CB 7030  
Chapel Hill, North Carolina 27599 -7030 
Phone: (919) 966- 3875 
E-Mail: napravs@med.unc.edu 
 
Clinical Program Manager  
JoAnn Kuruc, MSN, RN  
Clinical Program Director, The UNC Cure Center  
University of North Carolina at Chapel Hill Division of Infectious Diseases  
130 Mason Farm Road, 2nd Floor Bioinformatics 
Building, CB 7030  
Chapel Hill, North Carolina 27599 -7030 
Phone: (919) 966- 8533 
Fax: (919) 843- 7625 
E-Mail: joann_kuruc@med.unc.edu  
  
  
 
  
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   2   
STATEMENT OF COMPLIANCE  
The trial will be conducted in accordance with International Conference on Harmonization Good Clinical Practice 
(ICH GCP), applicable United States (US) Code of Federal Regulations (CFR) . The Principal Investigator will assure 
that no deviation from, or changes to the protocol will take place without prior agreement from the Investigational New Drug sponsor, funding agency, and documented appro val from the Institutional Review Board 
(IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants. All personnel involved in the conduct of this study
 have completed Human Subjects Protection and ICH GCP Training.  
 
The pro tocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to 
the IRB for review and approval.  Approval of both the protocol and the consent form must be obtained before 
any participant is enrolled.  Any amendment to the protocol will require review and approval by the IRB before the changes are implemented to the study.  All changes to the consent form will be IRB approved; a determination will be made regarding whether a new consent needs to be obtained from p articipants who 
provided consent, using a previously approved consent form.  
    
 
        
 
         
 
         
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   3 1  PROTOCOL SUMMARY  
1.1 SYNOPSIS  
 
Title:   
A Randomized, Phase II S tudy Comparing the Efficacy and S afety of 
Standard versus H igh-Titer Anti -SarS -CoV-2 Neutralizing Antibody Plasma 
in Hospitalized Patients with COVID -19 
 
Study Description:  This randomized, double -blinded, phase 2 trial will assess the efficacy and 
safety of anti-SARS-CoV -2 convalescent plasma in hospitalized patients 
with  less than 8 days of symptoms . Eligible participants will receive 
institutional-guided standard -of-care (SOC) and ABO -compatible 
convalescent C OVID -19 plasma (CCP). The  CCP units will be tested for the 
presence of anti -SARS- CoV-2 antibodies and pre -assigned as high -titer 
(CCP 1) or standard -titer (CCP 2) in a 1:1 randomization. Participants and  
clinical investigators will be blinded to the CCP titer group identities.  
 
Participants will be randomized within 48 hours of admission  to a COVID 
serv ice and will receive convalescent plasma within 24 hours of 
randomization. At least two  units of CCP will be transfused 4-24 hours 
apart on study D ay 0.  If available, a third unit may be administered . All 
participants will undergo a series of safety and efficacy assessments  pre-, 
during, and post -transfusion . Sample s for research will be collected on Day 
0 through Day 28, unless previously discharge d. Additionally, a fter 
discharge, participant s can provide longitudinal samples  collected at 1, 3, 
and 6-month timepoint s after the infusion .   
  
Objectives:  
 Primary Objectives  
Evaluate the safety of high neutralization titer anti- SARS- CoV2 plasma in 
patients hospitalized due to COVID -19, compared to standard 
neutralization titer anti- SARS- CoV2 plasma.  
 
Evaluate the efficacy of high versus standard neutralization titer anti -SARS-
CoV2 plasma to decrease length of hospitalization stay among patients 
hospitalized due to COVID -19. 
 Exploratory Objectives  
 
Evaluate the efficacy of high versus standard neutralization titer anti- SARS-
CoV2 plasma to improve clinical outcomes and mortality among  patients 
hospitalized due to COVID -19. 
 
Evaluate the safety and efficacy of high vs. standard total antibody  titer 
anti-SARS- CoV-2 plasma to increase survival and speed of hospital 
discharge in patients hospitalized du e to COVID -19. 
 
Evaluate the safety and efficacy of high vs. standard antigen- specific  titers 
of anti-SARS-CoV2 plasma to increase survival and speed of hospital 
discharge in patients hospitalized due to COVID -19. 
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   4  
Compare  length of hospitalization, clinic al outcomes , and mortality among 
patients hospitalized due to COVID -19, who consented to concurrent UNC 
IRB approved observational studies but did not  receive anti -SARS- CoV2 
plasma.  
 
Compare SARS -CoV2 viral recovery from anatomic sites in patients 
hospital ized due to COVID -19, who received high vs. low neutralization 
titer anti -SARS- CoV2 plasma. 
 Compare anti- SARS- CoV2 total antibody, antigen- specific antibody, and 
neutralizing antibody titers at 28 days, 3 months , and 6 months in 
participants  who received high vs. low neutralization titer anti- SARS- CoV2 
plasma.  
 Compare biomarkers obtained for clinical care in patients hospitalized due to COVID -19, who received high vs. standard neutralization titer anti- SARS-
CoV2 plasma.  
 
Primary endpoint:  
     Exploratory  endpoints: The primary safety endpoint will be assessed by the cumulative incidence 
of serious adverse events (SAEs) at study Day 14.  
 The primary efficacy endpoint will be assessed by days to hospital discharge (or discharge equivalent) following first dose of CCP.  
 
• Change in World Health Organization (WHO)  ordinal clinical status 
scale while hospitalized and at D ays 14 and 28 
• Change in  National Early Warning Score (NEWS) while hospitalized and 
at Days 14 and 28 
• Days of supplemental oxygen or greater, days of NIV/high -flow oxygen 
or greater, days mechanical ventilation/ECMO while hospitalized and 
respiratory support at D ays 14 and 28 
• In-hospital mortality  
• 28-day mortality  
• Change in SARS -CoV-2 RT-PCR Day 0, 3 (+/ -1), 7 (+/ -1) (and/or 
discharge date), 21, and 28 (if still hospitalized) from nasopharyngeal, endotracheal, fecal, and blood specimens   
• Change in anti -SARS- CoV-2 total antibody, antigen -specific antibody, 
and neutralizing antibody titers on D ay 28, 3 months , and 6 months  
 
Study Population:  This study will enroll up to 150  men and women, aged ≥ 18 years of age, 
hospitalized with COVID -19 infection , and reporting less than 8 days of 
symptoms prior to admission  to a COVID service . 
 For the purpose of this study we define symptoms as self -reported fever 
or documented fever ≥ 38.0  °C (100.4 °F). 
 
Phase:  Phase II  
 
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   5 Description of 
Sites/Facilities Enrolling 
Participants:  UNC Medical Center  
  
 
Description of Study 
Intervention: This randomized phase II study will assess the administration of at least 2 
units of CCP .  Participants will be randomized 1:1 to the blinded receipt of 
high or standard neutralizing SARS -CoV2 antibody on study D ay 0.  Clinical 
investigators will also be blinded to the CCP titer group identities.  
Standard of care will be defined as current standard treatment for 
hospitalized patients.  
 
Study Duration:  Up to 12 months  
 
Participant Duration:  An individual participant may be in this study for up to 6 months. The 
study participant will complete the study at D ay 28, but we would like to 
follow the participant if participant is able for up to 6 months following the 
transf usions for observation of immune response over time.  
  
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   6 Up to 150 :  Obtain informed consent. Complete screening; confirm eligibility ; 
obtain  medical history. Analysis will be done when  56 enrolled and in receipt of 
CCP. Enrollment will continue through analysis.  1.2 SCHEMA  
 
Prior to   
Enrollme nt 
   
 
      Visit 3: 
Day 0  
     
 
 Visits 4-9: 
Day 1 , 3, 7 
14, 21, 28  
   Visits 10  & 11 : 
Day 49 and  
Month 3  
   
 
 Visit 1 2: 
Month 6  
  Perform baseline and enrollment clinical status assessment s, risk assessment, 
examination, collect blood  and mucosal epithelial lining fluid   specimens (as 
available ) 
Administer convalescent plasma : 2 units (optional 3rd infusion) approximately 4 
to24 hours (prefer 4 -8 hours) apart  
 
 
Perform follow -up clinical status assessments, examination, and collect research 
samples.  Perform follow -up per schedule of activities, all clinical status assessments, 
examination, collect blood and mucosal epithelial lining fluid specimens (as 
available )  
Final Assessments  
Clinical status assessment s,  
examination, and collect  research 
samples   
Group 2  
CCP 2 (N= 75) Enrollment/ Randomiz ation  
Group 1  
CCP 1 (N= 75) 
 
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   7 1.3 SCHEDULE OF ACTIVITIES (SOA)  
 
Procedures  
Screening  Visit 1  
Baseline, 
Enrollment 
Randomization   
   Study Visit 3 
(CCP Transfusion)  
Study Visit 4 
Study Visit 5 
Study Visit 6 
 
Study Visit 7 
(if hospitalized ) 
Study Visit 8 
 (if hospitalized ) 
Study Visit 9 
End of Study (EOS) 
Visit 10 
Outpatient 
Longitudinal  Visit  
Study Visit 11 
Outpatient 
Longitudinal  Visit  
Final Study Visit 12 
Outpat ient 
Longitudinal  Visit  
Visit Day  # -2 -2 
to 0 0 1 3 7 14 21 28 49 90 180 
Visit Window in days      +/- 1 +/- 2 +/- 2 +/- 2 +/- 7 +/- 10 +/- 14 +/- 14 
Clinical Assessments              
Informed consent  X            
Demographics1 X            
Medical history1  X            
ABO typing ◊ X            
Record Admission ECG1  X           
Confirmed SARS -CoV-2 infection  X            
Randomization   X           
Assign Partcipant ID (PID)  X            
Assign Randomization ID (RID)   X           
Administer CCP ◊   X          
Concomitant medication review  X1  X1 X 1,8 X 1,8 X 1,8 X 1,8 X1,9 X9 X9 X9 
Physical exam  X1 X1 X1 X1 X 1,8 X 1,8 X 1,8 X 1,8 X1,9    
Height   X1           
Risk Assessment   X1           
Vital signs X X1 X1 X1 X 1,8 X 1,8 X 1,8 X 1,8 X 1,9 X9 X9 X9 
SOFA score  X1 X1 X1 X 1,8 X 1,8 X 1,8 X 1,8 X 1,9    
NEWS score  X1 X1 X1 X 1,8 X 1,8 X 1,8 X 1,8 X 1,9 X9 X9  
WHO Ordinal status  X1 X1 X1 X 1,8 X 1,8 X 1,8 X 1,8 X 1,9 X9 X9 X9 
Adverse event assessment    X1 X1 X 1,8 X 1,8 X 1,8 X 1,8 X 1,9 X9 X9 X9 
Laboratory Procedures ⸸             
Hematology1,2  X X X X8 X8 X8 X8 X8  X  
Coagulation1,2  X X X X8 X8 X8 X8 X8    
Serum chemistry1,2  X X X X8 X8 X8 X8 X8    
Pregnancy test 1,3 X            
Mucosal Lining Fluids 4, 5   X6,10  X6 8 X6,8,10 X6,8 X6,8 X6,9 X9,10  X9,10  X9,10  
Record Radiolog ic/Imaging 
assessment  1,7  X X X X8 X8       
Blood for Immunology & 
virologic assays 6   X  X8 X8 X8 X8 X9    
Blood for Immunology & 
virologic assay (optional study 
component) 5,10     X   X8   X X X X 
# Identify the day of discharge day as # of days from Day 0. Complete a chart note based on the events required (and obtainable ) per the next scheduled study 
visit. Collect remnant samples and data as available from this day. The collection of optional samples may or may not occur  due to  unknown nature of date 
and time of  discharge .  
◊ Per Hospital policy and guidelines.  
⸸ Please reference the study- specific laboratory schedule of sample collections to verify all collections and amounts.  
1 Information abst racted from medical record, as necessary and if available.  
2 CBC, differential, PT/INR, PTT, d -dimer, fibrinogen, albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, LDH, 
phosphorus, potassium, total protein, AST, ALT, sodium, C- reactive protein, IL -6. Collect if testing results available through routine clinical care.  
3 Serum pregnancy test on all women less than 60 years of age.  
4  Mucosal Lining Fluids include: Nasal fluids (NP swab, and/ or nasal epithelial lining strips (NELFS ), Oral fluids (saliva), Intestinal ( stool) and Resp iratory 
(endotracheal secretions  on intubated inpatient as available).   
5 Collections will be deferred if the participant refuses or is too clinically unstable to undergo sample collection.  
6 Collect remnant samples acquired for clinical care.  Collect remnant NP swab if obtained within 48 hours prior to CCP transfusion, if available in McLendon Lab.  
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   8 7 Chest x -ray and/or CAT scan (CT) chest if performed as part of routine clinical care.  
8 These samples and data will not be collected on participants once discharged from hospital.  
9  These data and samples will be collected from participants returning for outpatient visits.  
10 Collect samples for op tional immunology research (page 2 3). 
 
2  INTRODUCTION  
 
2.1 STUDY RATIONALE  
Convalescent plasma has appeared to be of benefit for the treatment of certain infectious diseases, including 
infections from respiratory viruses . [1,2]  Preliminary evidence indicates that CCP may possibly be of benefit for 
some patients with COVID -19, leading to improvement . [3,4]  
2.2 BACKGROUND  
The current outbreak of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), the novel virus that 
causes the clinically variable but often severe viral respiratory syndrome now known as COVID -19, is now a global 
pandemic that threatens the lives of millions of people across the world. As of April 16th, 2020, there have been 632,548 confirmed cases and 31,071 deaths due to COVID -19 in th e United States alone, with the former likely 
being a gross underestimate of the actual incidence and prevalence (U.S. Centers for Disease Control and Prevention [CDC] 2020). Reported mortality rates have demonstrated some variability between countries ; 
however , all data to date indicate that SARS -CoV-2 is a highly infectious and lethal virus in the elderly population, 
as well as in patients with comorbidities that are exceedingly common in the U.S., and can in fact be fatal in patients of any age.  
 Com pounding the formidable natural course of SARS -CoV-2 is the absence of any pre -existing immunity to it in the 
human population and the resulting exponential growth of clinically severe infections . 
 Current options for treatment  
Currently, the treatment of patients hospitalized with C OVID -19 is supportive, ranging from supplemental oxygen 
to invasive ventilation in nearly 75% of those admitted to the ICU.  [5] Multiple investigational therapies are 
currently under study in clinical trials; however, no therapy  has been proven. Importantly, many of these 
therapies, including the RNA -dependent RNA polymerase inhibitor, remdesivir, that is effective in pre -clinical 
animal models [6], were not specifically developed to target SARS -CoV-2. Similarly, although hydroxy choloroquine 
might inhibit endosomal -mediated viral cellular injury, this agent is not specifically active against SARS -CoV-2. In 
addition, while anti-IL -6, anti -IL1β, and other monoclonal antibodies might attenuate disease severity by 
modulating cytokine release syndrome, the mechanisms of these agents are not expected to enhance innate or 
adaptive immune responses to promote viral clearance. Lastly, even if these agents are effective, the ability to mass -produce on a scale necessary to address this global pandemic is limited. SARS- CoV-2 is highly transmissible 
and is likely to spread in regions that may lack access to novel pharmaceuticals, but have existing blood donation 
and re -infusion capacity.  
 
Rationale for the use of CCP for the treatment of severe C OVID -19 
COVID -19 convalescent plasma (CCP) represents the only current therapeutic option against SARS -CoV-2 that has 
the potential to augment virus -specific immune responses and is also scalable to deploy rapidly. The hypothesis 
for the efficacy of CCP is that plasma from COVID -19-recovered patients contains antibodies that are directed 
against, and could neutralize, SARS -CoV-2. This concept of passive antibody therapy is established in clinical 
practice through the use of intravenous immune globulin (IVIg).  [7-9] IVIg provides concentrated passive antibody 
to augment humoral immunity and therefore can prevent and have therapeutic activity against some viral and 
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   9 bacterial infections. Historically, plasma from recovered patients has  been used to treat other viral respiratory 
infection outbreaks including SARS -CoV-1 and Influenza.  [1, 10]  
Experience from SARS -CoV-1 shows that such convalescent plasma (CP) contains neutralizing antibodies to the 
relevant virus. [11] During 2009 H1N1, t here was an 80% reduction in risk of death in severely ill patients who 
received CP versus controls who decline d it (OR: 0.2, 95% CI: 0.06- 0.69, P=0.011).  [1] Convalescent serum was also 
used in the 2013 African Ebola epidemic. A small non -randomized study  in Sierra Leone revealed a significant 
increase in survival for those treated with convalescent whole blood relative to those who received standard 
treatment. [12] A systematic review of CP use in severe acute respiratory infections identified 32 studies between 
1919 and 2011 that collectively suggested a similar reduction in risk of death with this approach (OR: 0.25, 95% CI: 0.14- 0.45, I
2=0%).  [13] Although this historical using CP for viral outbreaks, CCP as a plausible intervention for 
COVID -19, randomized controlled trials are needed to establish the efficacy of CCP.  
Two uncontrolled case series encompassing 15 CCP -treated patients in China have been published.  [3, 4]  Both of 
these studies reported signs of clinical improvement days after rec eiving CCP  in doses of either 1 unit (200 mL) or 
2 units (400 mL). There were no reports of harm. CCP -treated patients in one study were found to have lower 
levels of IL -6, IL-10, and TNFα compared to controls at corresponding timepoints, suggesting that CCP could 
potentially exert a dampening effect on the cytokine release syndrome (CRS) suspected to be involved in the 
pathogenesis of severe COVID -19. [3, 14]  In another pilot study in Wuhan, China CCP collected from SARS -CoV-2 
positive patients 3 weeks following the onset of illness was used to treat patients diagnosed with ‘severe COVID -
19’ as defined by WHO Interim Guidance and the Guideline of Diagnosis and Treatment of COVID -19 National 
Health Commission of China. [4] Ten patients were treated with one dose of CC P (200ml, >1:640 titer by 
neutralization assay) at a median of 16.5 days (11 -19.3 days) post -onset of symptoms. A COVID -19 positive control 
cohort was retrospectively identified and matched by demographics, comorbidities, and severity of illness. There 
were no serious adverse reactions or safety events recorded with convalescent plasma, including no reported 
transfusion -related reactions, transfusion -related acute lung injury, or antibody -mediated enhancement of 
infection. In the treatment group, there were 0 deaths, 3 discharges , and 7 patients improved, whereas there 
were 3 deaths and 7 patients who improved in the control group (p < 0.001).  [4] In addition, 2 of 3 patients in the 
treatment on mechanical ventilation were weaned to high flow nasal canula, w hich was discontinued in one 
patient. There was a reduction in blood RNA viral load in 7 of 10 patients on day 6 post -convalescent plasma 
therapy as well as improvement in laboratory markers. There were also varying degrees of improvement in 
pulmonary lesi ons on chest CT after convalescent plasma therapy. In another case series from China, five severely 
ill patients with COVID -19, all on mechanical ventilation received convalescent plasma within 22 days of 
admission.  [3] Temperatures normalized in 4 of 5 pa tients within 3 days, NEWS scores decreased, and there was 
improvement in oxygenation and Acute Respiratory Distress Syndrome  (ARDS) resolution. All survived, with 3 
discharged home and 2 in stable condition. These reports suggest convalescent plasma may hold promise for ameliorating the severity of COVID -19 and deserves immediate investigation for this indication.  
Justification for a randomized FDA -standard versus high- anti anti -SARS -CoV- 2 neutralizing antibody titer plasma 
design  
The therapeutic benefit of CCP is hypothesized to be due to the presence of high concentrations of antibodies 
that neutralize the virus. When present in high  concentrations, these neutralizing antibodies interrupt viral 
replication and halt disease progression. [15] Data from China suggests that by 14 days after onset of symptoms 
from SARS -CoV-2, most patients have developed evidence of antibody responses. [16] Although this humor al 
immune response appears nearly universal, there is variability in the neutralizing properties of the serum of these 
individuals. In a study comparing total antibody to neutralizing antibody using serum neutralization assays, the presence of co -morbidities was associated with lower titers of neutralizing antibody at similar timepoints of the 
disease process.  [17] Co-morbidities also associate with more severe CO VID-19 outcomes and more prolonged 
viral shedding. [18]. This suggests tha t the ‘quality’ and/or quantity of neutralizing antibodies varies between 
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   10 individuals. In addition, data from humoral responses in SARS -1 also demonstrates that specific  antibodies persist 
for >3  months. [19] 
When used for therapy, the optimal dose of neut ralizing antibody in plasma has not been well defined. Either 
under -dosing by using plasma with inadequate neutralizing antibody titer, or over -dosing could alter the safety 
and efficacy profile. A theoretical, but unproven complication of administering CC P is the phenomenon of 
antibody -dependent enhancement of infection (ADE). ADE occurs when cross -reacting antibodies and/or low 
levels of neutralizing antibody against a viral pathogen can paradoxically worsen the viral syndrome. Although the 
ADE phenomenon  has not be en described for COVID -19, this risk needs to be considered.  [20] The clinical 
relevance of ADE has been best elucidated in dengue disease, wherein secondary infection by the dengue flavivirus can be considerably more severe than primary infection due to the enabling of viral entry into FcγR -
expressing cells by antibodies generated against the initial viral serotype. A recent study of a long -term pediatric 
cohort in Nicaragua suggests that this process occurs within a narrow window of pre -existin g antibody levels, 
above which the patient is protected from clinically significant ADE. [21] Human coronavirus infection is not 
known to be clinically exacerbated by ADE, although ADE has been demonstrated to occur in a feline coronavirus model. [22] ADE has been demonstrated to occur in both SARS -CoV-1 and MERS -CoV infection in vitro via 
conformational change of the spike protein induced by neutralizing antibody ligation that triggers antibody -
dependent and non - endosomal viral entry into FcγR -expressing cells. In this model, enhanced viral entry can be 
overcome by higher antibody leve ls that saturate the FcγRs. [23] Although the historical data on CP use during 
past viral outbreaks do not suggest that ADE- mediated worsening of COVID -19 severity is likely to occur, these 
data nevertheless suggest that it remains a possibility, which adds further justification for an randomized control trial (RCT) design.  
Publications to date have infused CCP with neutralizing antibody titers ranging from ≥1:40  [3] to ≥1:640 [4] to 
treat COVID -19. The FDA has authorized the use of CCP on a compassionate use basis with a recommended 
minimum neutralizing antibody titer of ≥1:160 or ≥1:80 if rare ABO -type matching is required. While there is little 
evidence to establish a minimum effective neutralizing antibody titer for SARS -2, in a prospective cohort of 
patients with H1N1 who consented to CP with neutralizing antibody titer of ≥1:160, there was a significant 
reduction in mortality (20.0% vs 54.8%; P=0.01) and more rapid decline in respiratory tract viral loads when compared with patients who declined plasma . [1] In a Phase II study, a greater proportion of patients receiving CP 
with neutralizing antibody titer ≥1:80 in addition to standard of care, compared with standard of care alone, improved clinical status by day 7 (20% vs 38%; p=0.041).  [2] A phase III,  blinded randomized study compared CP 
with anti -influenza neutralizing antibody titer ≥1:80 given early after symptom onset, compared with low- titre CP 
(≤ 1:10), failed to show any significant benefit.  [24] All patients also received anti -viral therapy with oseltamivir, a 
drug with proven anti -influenza activity.  
A large number of patients with COVID -19 will receive CCP through the FDA authorized compassionate use 
mechanism. This registry should provide important safety data, and will be informative regarding efficacy ; 
however, the level of evidence will not achieve that of a randomized control trial. Several have proposed to use fresh -frozen plasma (FFP) as a placebo. FFP as a placebo has the benefit of blinding, and addresses the possibility 
that compone nts of CCP other than the neutralizing antibodies themselves could exert a therapeutic effect, which 
could favorably impact clinical outcomes. However, absent a standard of care arm, an FFP compared with CPP design will not allow for recognition of possible benefits from FFP. We therefore propose an alternative trial design that compares the FDA -recommended minimum titer of ≥1:160 with CCP containing very high titer 
neutralizing antibody ≥1: 640. This allows all participants  to receive potential benefit, whi le intentionally 
evaluating the paradigm the most beneficial component of CCP is neutralizing. Our study will also centralize the neutralizing antibody assay, which can be difficult to interpret across various assay methods. If high -titer -CCP 
rather than F DA-standard -titer CCP ultimately proves to improve clinical outcomes in the study population, it 
would provide support that clinical benefit would be attributable to the antibody present in the convalescent donor source, and not to components common to all  donor plasma. A dose -dependent clinical benefit would 
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   11 inform screening criteria for possible CCP donors, including inter- individual factors that might be identified as 
predicting high -neutralizing titer plasma as well as intra- individual factors such as t ime since viral diagnosis and/or 
viral clearance. Knowing how donor factors predict neutralizing antibody titer could help focus CCP collections to 
increase the likelihood of banking CCP with the maximum therapeutic potential.  
Given that the expected role of CCP is to leverage passive immunity to accelerate viral clearance, CCP would best be given early in the disease course. 50% of patients develop a humoral response within the first 7 days of symptoms. [16] It is therefore optimal to intervene with CCP at this earlier timepoint if possible. One potential 
side effect of passive antibody therapy, however, is interference in the development of humoral immunity in the host. This phenomenon is well -described in the setting of Measles vaccine responses in infant s where -in the 
presence of maternal anti- measles antibodies attenuate post- vaccine seroconversion. [25] Thus, CCP at different 
titer ranges might not only have different dose -dependent effects during acute infection, but could differentially 
alter natural immune development during the convalescent period. It is not yet known whether natural immunity 
to SARS- 2 is sustained. In the absence of an available vaccine, it is important to evaluate not only the effect of CCP 
during acute severe illness, but the potential resulting modulation in host -derived humoral immunity, and 
therefore risk of re -infection.  
There are limited data on use of convalescent plasma in pregnancy. A non -randomized comparative study that 
evaluated use of convalescent plasma for Ebola Virus Disease reported that eight out of 84 participants were 
pregnant and that mortality was 25% among pregnant women and 32% among non -pregnant individuals after 
receiving plasma treatment . [26] A case series of 4 Chine se patients, among whom one was pregnant, received 
convalescent plasma and had recovered from SARS -CoV-2 infection . [27] We do not have robust data of using 
convalescent plasma in pregnancy as most trials have excluded pregnant patients.  IVI g therapy , however , is safe 
to give during pregnancy and is often used in those with inflammatory disorder and/or autoimmune conditions. Given the limited experimental treatment options for women with SARS -CoV2 , we will not exclude pre gnant 
women from this trial. We will document the presence or absence of pregnancy prior to administering study product , and ensure that participants are informed if they are pregnant prior to receipt of CCP . 
2.3 RISK/BENEFIT ASSESSMENT   
 
2.3.1  KNOWN POTENTIAL RISKS  
1. Risks of receiving CCP:  
Convalescent plasma represents a licensed blood product, for which the risks are well described. In a safety analysis of 5,000 patients treated with CCP, the risk of a severe transfusion reaction (c or d 
below) was less than 1% and no fatalities were attributed to CCP
. The risks associated with the 
administration of plasma i nclud e but are not limited to the following transfusion reactions : 
a. allergic transfusion reactions  (1- 3%),  
b. anaphylactic reactions (<0. 01%),  
c. transfusionassociate d circulatory overload  (TACO)  (1%) ,  
d. transfusion -related acute lung injury (TRALI ) (<0.1%) ,  
e. hemolytic transfusion reactions (<1% or very rare),  
f. viral and bacterial infections ( very rare or <1%) , and  
g. febrile non -hemolytic transfusion reactions (<1%)  
 
Plasma is collected per FDA Guidelines.  [28] There are additional FDA requirements for COVID -19 
plasma donations  which include:  
a. Evidence of COVID -19 documented by a laboratory test either by:  
i. A diagnostic test (e.g., nasopharyngeal swab) at the time of illness  
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   12 OR 
ii. A positive serological test for SARS -CoV-2 antibodies after recovery, if prior diagnostic 
testing was not performed at the time COVID -19 was suspected.  
b. Complete resolution of symptoms at least 14  days prior to donation . 
CCP u nits collected at the University of North Carolina’s (UNC) Blood Donation Center  (BDC) will be 
tested for the presence of anti -SARS- CoV-2 antibodies prior to transfusion or units.  
 
There are several theoretical risk s associated with the administration of convalescent plasma: 
a. Antibody -mediated enhancement of infection (ADE). ADE can occur in viral diseases, such as 
dengue and involves an enhancement of disease in the presence of certain antibodies. For coronaviruses, several mechanisms of ADE have been described, including the theoretical concern that antibodies to one type of coronavirus could enhance infection to another strain.  
[23] It may be possible to predict the  risk of ADE in SARS- CoV-2 experimentally, as proposed 
for MERS. [23] Preliminary studies in the Baric and De Silva laboratories at UNC (unpublished) 
suggest minimal or no cross -reactivity between SARS -CoV-2 antibodies and other 
coronaviruses known to circ ulate in our community. Since the proposed use of convalescent 
plasma in the COVID -19 epidemic would rely on preparations with high titers of antibody 
against the same virus, SARS2 -CoV-2, ADE may be unlikely. Available evidence from the use 
of convalescent  plasma in patients with SARS -1 and MERS demonstrated it is safe [13] and 
there were no adverse effects in a pilot study of patients with COVID -19. [4] Nevertheless, 
caution and vigilance will be exercised to use clinical and laboratory measures to detect 
evidence of enhanced infection.  
b. Risk is that antibody administration to those exposed to SARS -CoV-2 may prevent disease but 
modify the immune response such that those who are treated may mount attenuated immune responses.  This may leave them vulnerable to subsequent re -infection. Passive 
antibody administration before vaccination with respiratory syncytial virus attenuated humoral but not cellular immunity . [27] This will be investigated as part of this clinical trial by 
comparing early (first month) and late (up to 6 months) immune responses in those who 
receive standard of care and those who additionally received convalescent plasma. If 
responses differ, those with attenuated levels could be vaccinated against COVID -19 when a 
vaccine becomes available.  
 There is also the risk that convalescent plasma may be ineffective.  
 
2. Risk of Blood Draw  (<1%)  
Blood drawing may cause pain, bruising, and may infrequently cause a feeling of lightheadedness or fainting. Rarely, it may cause infection, vein irritation (called phlebitis) or blood clot at the site where the blood is taken. We will minimize risk by using aseptic technique and universal precautions.  
 
The risks to participants entailed by this study are minimal as research labs will be collected as part of 
the clinical care and other research studies , eliminating a separate collection and phlebotomy for 
these blood samples. This will also decrease the burden of large amount of extra blood collected on participants acutely ill.    
 
3. Risks of Intravenous (IV) Infusion  
Problems from use of an IV are generally mild and may include pain, bruising, minor swelling or bleeding at the IV site, and rarely, infection, vein irritation (called phlebitis), or blood clot. Risk will be minimized by using sterile technique and univers al precautions.  
 
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   13 The placement of an intravenous catheter can allow for the development of bacteremia because of 
the contact between the catheter and unsterile skin when it is inserted. This will be prevented through careful decontamination of local skin prior to catheter placement and through the use of infection control practices during infusion. Product contamination will be prevented by the use of aseptic technique in the pharmacy and universal precautions during product administration.  
 
4. Risk of Nas opharyngeal (NP)  Swab, Oropharyngeal (OP) Swab , Nasal S wab , Nasal  Strips  and other 
body fluid collections   
Collecting a respiratory swab may cause transient discomfort. Collection of the nasal epithelial lining 
fluid via nasal swab or  strips may cause transient discomfort or the very rare risk (<1%) of aspiration 
of the filter paper. Discomfort and risk will be  minimized by using experienced clinical staff at each 
site, and samples will be taken at the same time as clinical samples in order to minimize these risks. 
Nasal strips and/ or nasal swabs will be self- collected when possible by the participants .  
 Collection of stool, endotracheal and saliva secretions is not expected to cause any excessive 
discomfort . Stool and saliva will be self-collected whe n possible by the participants.  
 
5. Unknown Risks   
New therapies can lead to unexpected, incidental findings that could have a potential effect on the participant’s health. Upon confirmation of a potential health or reproductive effect, the study team will notify participants impacted by the new information and will advise proper medical follow -up 
when indicated. If findings require more immediate medical attention, the study PI in conjunction with the study coordinator will assist participants in getting an appropriate medical care appointment.   
 
6. Risk of breach of confidentiality :  
Data gathered on study participants will include but not be limited to the following: their age, gender, race, laboratory -confirmed COVID -19 infection, and COVID -19 specific symptoms history . In the early 
phase of the epidemic, a COVID -19 diagnosis may carry significant stigma. Standard measures will 
ensure confidentiality of participants and data generated, as described  later in the protocol.
 
 
2.3.2  KNOWN POTENTIAL BENEFITS  
The most important potential benefit is that CCP may reduce progression to respiratory failure in patients with COVID -19 and early respiratory symptoms, such as shortness of breath, cough, chest 
pain, and pulmonary infiltrates. The benefit of plasma is exp ected to result in  improvement s in 
symptoms, oxygenation, and preventing the need for mechanical ventilation and possibly reduced mortality, earlier hospital discharge, and better clinical outcomes. Based on historical experience with antibody administration, it is expected to be effective if administered relatively early in the disease  
course . [15] CCP was safe, appeared to reduce symptoms, and improved oxygenation in a non -
randomized open label study of patients with more advanced COVID -19 disease in Wuhan, China . [3, 
4] 
 
There may be no potential benefit of collection of samples other than the knowledge that one is 
helping advance science that may lead to understand ways to promote improved treatment.  
 
The experimental agent remdesivir may soon be available to some patients with COVID -19 via an 
expanded access program. While the clinical criteria to allow expanded access to remdesivir are not 
currently known, it is likely that many COVID -19 p atients eligible for CCP may not be eligible for 
remdesivir. However, if patients are eligible for remdesivir and desire to receive CCP, to avoid 
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   14 depriving them of a possible benefit, we will allow co -enrollment (if allowed by the remdesivir 
program).  
 
2.3.3  ASSESSMENT OF POTENTIAL RISKS AND BENEFITS  
Given historical data showing convalescent plasma was safe and possibly effective in patients with 
SARS- 1, [10, 13]  and emerging data from China suggest it is safe and possibly effective in patients with 
severe COVI D-19 along with the relative lack of other readily available therapeutic options for severe 
or life -threatening disease, the benefits of its use in those at high risk for severe disease outweigh the 
risks.  
 
However, for all patients in whom CCP  administrat ion is considered, a risk -benefit assessment will be 
conducted to assess all individual variables. This protocol proposes a randomized controlled trial to 
assess the efficacy of CCP in preventing respiratory progression in patients with COVID -19. A recent 
JAMA editorial by experts note the importance of randomized clinical trials to demonstrate efficacy of this approach and to change the course of the epidemic.  [3] 
 There are limited data on potential risks and/or benefits  for pregnant women and possible ef fects on 
the fetus .  Pregnancy can cause changes in the coagulation and fibrinolytic systems and CCP  may 
potentially benefit individuals by providing the coagulation factors.   
  There is sufficient expectation that the proposed NP swabs,  OP swab s, nasal swab , nasal 
strips ,plasma, stool, endotracheal, saliva,  and blood collections will be safe and well tolerated.  
 
 
3 OBJECTIVES AND ENDPOINTS  
 
OBJECTIVES  ENDPOINTS  
Primary   
Evaluate the safety of high neutralization titer anti- SARS- CoV2 
plasma in patients hospitalized due to COVID -19, compared to 
standard neutralization titer anti- SARS- CoV2 plasma.  
Evaluate the efficacy of high versus standard neutralization titer anti-SARS- CoV2 plasma to decrease length of hospitalization 
stay among patients hospitalized due to COVID -19. The primary safety objective will be assessed by the cumulative incidence of serious adverse events (SAEs) at study Day 14.  
The primary efficacy endpoint will be assessed by days to hospital discharge (or discharge equivalent) following CPP first dose .   
 
Exploratory   
1. Evaluate the efficacy of high versus standard neutralization 
titer anti -SARS- CoV2 plasma to improve clinical outcomes and 
mortality among patients hospitalized due to COVID -19. 
     
 
 
 1. Change in  WHO ordinal clinical status scale 
while hospitalized and at D ay 28 
 Change in National Early Warning Score (NEWS) while hospitalized and at Day 14 and 
Day 28 
 Days of supplemental oxygen (if applicable) 
while hospitalized at D ay 14 and Day 28  
 
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   15 OBJECTIVES  ENDPOINTS  
 
 
         
2. Evaluate the safety and efficacy of high vs. standard total 
antibody  titer anti -SARS- CoV2 plasma to increase survival and 
speed of hospital discharge in patients hospitalized due to 
COVID -19. 
  
3. Evaluate the safety and efficacy of high vs. standard antigen -
specific  titers of anti -SARS- CoV2 plasma to increase survival and 
speed of hospital discharge in patients hospitalized due to 
COVID -19. 
 
4. Compare length of hospitalization, clinical outcome s, and 
mortality among patients hospitalized due to COVID -19, who 
consented to concurrent UNC IRB approved observational 
studies but did not receive anti -SARS- CoV2 plasma.  
 
5. Compare SARS- CoV2 viral recovery from anatomic sites in 
patients hospitalized due to COVID -19, who received high vs. 
standard neutralization titer anti- SARS- CoV2 plasma.  
  
 
6. Compare anti-SARS-CoV -2 total antibody, antigen- specific 
antibody, and neutralizing antibody titers at 28 days, 3 months , 
and 6 months in participants  who received high vs. low 
neutralization titer anti- SARS- CoV2 plasma.  
  7. Compare biomarkers obtained for clinical care in patients hospitalized due to COVID -19, who received high vs. standard 
neutralization titer anti- SARS- CoV2 plasma.  Days of NIV/high -flow oxygen (if applicable) 
while hospitalized and at D ay 14 and Day 28 
 Days of Invasive ventilation/ECMO (if applicable) while hospitalized and at Day 14 
and Day 28 
 In-hospital mortality  
 28-day mortality  
 
 
2. Same as above  
   
 3. Same as above  
  4. Same as above  
 
 
5. SARS- CoV-2 RT -PCR on Day 0, 3 (+/ -1), 7 (+/ -
1) (and/or discharge date), 21, and 28 (if still 
hospitalized) from nasopharyngeal, endotracheal, fecal, and blood specimens  
 
6. Serum anti-SARS- CoV-2 total antibody, 
antigen -specific antibody, and neutralizing 
antibody titers on D ay 28, 3 months , and 6 
months  
 7. Lymphocyte and neutrophil counts, 
hematological and coagulation measurements 
(D-dimer, fibrinogen, PT), renal and liver 
function, and inflammatory markers (ferritin, CRP, and IL -6 if available) during 
hospitalization on Days 0, 1, 3, 7 (and/or day 
of di scharge), 14, 21, and 28.  
 
 
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   16 4 STUDY DESIGN  
 
4.1 OVERALL DESIGN  
This randomized, double -blinded, phase 2 trial will assess the efficacy and safety of anti- SARS- CoV-2 convalescent 
plasma in hospitalized patients with less than 8 days of symptoms. S ymptoms for this study are defined as self -
reported fever or documented fever ≥ 38.0 °C. 
We plan to enroll up to 150 participants and all will receive CCP. Participants will be randomized in a 1:1 ratio to 
receive institution -guided standard -of-care together with CCP  of either high or standard titer of SARS- CoV2 
neutralizing antibodies.  Information collected following plasma administration will include adverse events , 
participant,  demographics, clinical status and laboratory and radiographic data collected for routine clinical care, 
acute care resource utilization, and characteristics of the CCP administered. The study w ill undergo  primary  
analysis when 56 p articipants  are enrolled and received CCP. Enrollment will continue during the analysis period 
to provide  potential for benefit to hospitalized persons as well as to increase enrollment number for additional 
analysis. Following primary analysis we will close the study if a conclusion can be made, or propose an additional 
analysis plan for additional enrollees.  
The study will also create a biobank of blood  and mucosal lining fluids inclu sive of  nasal fluids (NP swab, and/or 
nasal epithelial lining strips (NELFS), oral fluids (saliva), intestinal ( stool) , and resp iratory (endotracheal secretions)  
from hospitalized participants who receive d CCP early in the disease process . The study will collect sa mples  prior 
to the first administration of CCP through 28 days following this transfusion  participation through 6 months is 
optional. The study will primarily collect r emnant blood and tissue samples  on all participants during their 
hospitalization. We will collect real time  samples on a subset of participants who agree to provide optional 
samples . 
 
Biospecimens will also be obtained at timepoints per SOA, section 1. 3. The  study will attempt to collect as many 
specimens as possible, understanding that many collections will not be possible due to COVID -19 restrictions, 
access , and participant’s clinical condition. The  purpose of these biospecimens will be  to  measure the relationship 
between administrat ion of CCP  and viral load dynamics (from blood, nasal/respiratory fluids, saliva, and stool ), 
immune responses, and biological indicators of COVID -19 disease severity. Biospecimens will be used to study and 
develop research assays to understand the antibody and cellular responses to SARS -CoV-2 coronavirus after 
human infection.  
 The study will collect data from hospitalized patients, who opted not to be on this study and whose data is 
captured in the UNC IRB Study #: 20 -1095  entitled: IGHID 12018 - U NC COVID Cohort (UCC) . 
 
4.2 SCIENTIFIC RATIONALE FOR STUDY DESIGN  
Convalescent plasma collected from individuals who have recovered from a prior viral infection for the passive 
transfer of antibodies has been used at various times over the past century. There has been some evidence for 
benefit against hepatitis B, polio, measles, influenza, Ebola, and other pathogens.  [12] Results from small case 
series during the prior MERS and SARS coronavirus outbreaks documented safety and faster viral clearance following convalescent plasma administration, particularly when given early in the disease course.
 Additionally, 
there is preliminary clinical evidence that suggests that convalescent plasma might provide benefit to individuals with SARS -CoV-2 infection and manifestations of COVID -19. [3, 4] Patients with COVID -19 who have received 
convalescent plasma in these reports also received various other therapies, including anti- virals, anti-bacterial, 
and immune modulators. The use of such empiric therapies is currently a co mmon practice in medical centers 
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   17 treating hospitalized patients with COVID -19. As such, the additional benefit and/or safety of convalescent plasma 
to local standard of care practices is unknown. Several current randomized control trials in hospitalized patients 
with moderate and/or severe disease are designed to compare the effect of convalescent plasma to non -
convalescent FFP. However, such a trial design cannot account for the effect of non -antibody components plasma 
that could modify the disease course.  Based on the preliminary evidence of possible efficacy of convalescent 
plasma, and an expected evolution in local standard of care practices, this protocol is designed to ascertain the dose -dependent safety and efficacy of convalescent plasma with neutralizing antibody in standard compared with 
high titer range. In addition to standard of care in individuals with documented SARS -CoV-2 disease at acute care 
facilities who are within 8 days of onset of symptoms, defined as self- reported fever or fever ≥38.0  °C. 
 
The study design allows for the collection of blood and tissue samples for research to expand our ability to understand SARs -CoV-2 and the efficacy of CCP  through the analysis of convalescent blood derived from different 
de-identified donors and the c linical and biological outcomes of patients treated with CCP .
 
 
4.3 JUSTIFICATION FOR DOSE  
Two units of plasma ( approximately 200-250 mL each ) containing anti -SARS2 -CoV-19 antibodies at a  minimum  
titer of 1:160 per May 1, 2020 FDA guidelines ( https://www.fda.gov/vaccines -blood -biologics/investigational -new -
drug- ind-or-device -exemption -ide-process -cber/recommendations -investigational -covid- 19-convalescent -plasma ) 
will be infused. Functional neutralization assays are performed at UNC -CH. Should f unctional neutralization assays 
not be available, an ELISA targeting SARS -2-specific IgG will be used as a surrogate to determine titer. ELISA is a 
widely available methodology and the de Silva and Baric laboratories at UNC -CH are cross -validating these tw o 
methods. For standard titer units, the neutralization assay titers will range from ≥1:160 ≤1:640  and for the high -
titer units the neutralization assay titers will exceed 1:640.  
Dosing is based on experience with previous use of convalescent plasma therapy in SARS -1 where 5 mL/kg of 
plasma at titer ≥ 1:160 was utilized.  [10] For a 70 k g person , plasma volume is estimated at 2800 mL (40 mL/kg 
x70 kg) with baseline anti -SARS -CoV-2 titer of 0. For example, if protective titer was 1:25 and each unit had titer of 
1:160, ~250 mL can achieve this ([250/(2800)] x 1:160>1:25).  
 
4.4 END OF STUDY DEFINITION  
The end of study is defined as participants completing study follow -up through Day 28, or had an adverse event  ≥ 
Grade 3 related to study product  or death occurr ing prior to Day 28. Optional outpatient f ollow -up visits extend 
through month 6 for observation of immune response  over time.  
5 STUDY POPULATION  
 
5.1 INCLUSION CRITERIA  
 
1. Age at least 18 years  
 
2. Ability and willingness of participant or L egally Authorized Representative (LAR) to give written informed 
consent.  
 
3. Laboratory confirmed diagnosis of infection with SARS -CoV-2 by PCR  
 
4. Hospitalized for COVID -19 with one or more  resp iratory or gastrointestinal (GI) symptoms : 
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   18  
• COVID -19 associated respiratory symptoms include but are not limited to:  cough, 
shortness of breath, difficulty breathing, or sore throat  
• COVID -19 associated GI symptoms include but are not limited to:  loss of taste, loss of 
sense of smell, diarrhea, nausea, or vomiting,  
 
Note:  Respiratory and GI symptoms other than those listed above, must be noted as acceptable and 
signed by study PI or designee.    
 
5.2 EXCLUSION CRITERIA  
1. Receipt of pooled immunoglobulin in past 30 days  
2. Current or prior enrollment in a SARS- CoV-2 antibo dy or T- cell therapeutic study.  
Note: Patients enrolled  on other randomized controlled trials of pharmaceutical and/or non -
pharmaceutical interventions for COVID -and meet ing eligibility criteria will not be excluded, as 
determined by study PI (or designe e) on a case -by-case basis  and as allowed by eligibility criteria of the 
other trials . 
3. Contraindication to transfusion or history of prior reactions to transfusion  blood products . This may 
include religious or cultural objections to receiving blood products and transfusions.  
4. ABO -compatible titered plasma is not available  
5. > 10 days from noted COVID -related subjective or objective fever  at randomization . Patients withou t 
subjective or objective fever, > 10 days from symptom onset as determined by study PI.  
 
5.3 STRATEGIES FOR RECRUITMENT AND RETENTION  
Patients eligible for this trial will be identified by their treating providers. Study coordinators will follow up with partici pants during their hospitalization and after discharge.  
6 STUDY INTERVENTION  
Participants  will be randomized in a 1:1 ratio to receive standard of care and study product (CCP) of high or 
standard titer. Standard of care will be defined as current standard treatment for hospitalized patients at respective study site. It is expected that standard of care may vary as advances are made in therapeutic options 
and data from ongoing trials becomes available.  
 
6.1 STUDY INTERVENTION(S) ADMINISTRATION  
 
6.1.1  STUDY INTERVENTION DESCRIPTION  
 
ABO compatible CCP  will be obtained from the Institution’s  Transfusion Medicine Service . CCP will be 
administered according to standard hospital procedures per May 1, 2020 guidelines 
(https://www.fda.gov/vaccines -blood -biologics/investigational -new -drug- ind-or-device -exemption -ide-
process -cber/recommendations -investigational -covid- 19-convalescent -plasma).  Plasma units will be 
labeled with an International Society of Blood Transfusion (ISBT) label.  
6.1.2  DOSING AND ADMINISTRATION  
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   19 Two  units ( a total of ~ 400-500 mL) of plasma with antibodies to SARS -CoV-2 measuring a minimum 
neutralization titer of 1:160 as per May 1 , 2020 FDA guidelines  will be administered. The standard titer 
group will receive units ranging from ≥ 1:160 ≤ 1:640 and high -titer group will receive units exceeding 
1:640. Whenever possible, both units will be derived from the same donor. The 2 units will be 
administered between 4 -24 hours apart, and preferentially between 4 -8 hours apart when feasible. If 
available, a third unit from a matched donor may be infused.  At the discretion of the treating physician, 
one unit may be administered if the patient experiences an adverse reaction after the first transfusion  
and/or is deemed to be at high risk of circulatory overload.  
1. CCP will be administered within 24 hours of randomization . 
 
2. CCP will be infus ed at rate per institutional guidelines/SOPs for the administration of plasma. 
 
3. Premedications may be given  per institutional guidelines/SOPs for the administration of plasma. 
Pretreatment will be administered to minimize transfusion reactions (e.g., acetaminophen, 
diphenhydramine) .  
 
4. If an AE develops during infusion, the infusion may be slowed or stopped per the treating provider ’s 
decision per institutional guidelines/SOPs  for the administration of plasma. . Most reactions to plasma 
transfusions are relatively minor and the infusions are generally continued.  
 
6.2 PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY  
 All convalescent plasma units will be prepared and stored per instiutitional SOPs as governed by the the FDA CFR Title 21 . 
6.3 MEASURES TO MINIMIZE BIAS  
 
Randomization  
Participants will be randomized 1:1 to one of two treatment arms :  
CCP1: SOC and high titer anti -SARS- CoV-2 antibody plasma  
CCP2 : SOC and standard titer  anti-SARS- CoV-2 antibody plasma   
Enrolled patients will be assigned to an arm using a permuted block randomization, with block size randomly varied between 2, 4 , or 6. We will generate a list of random numbers using the SAS procedure PLAN.  
 
Blinding   
Study personnel,  participants , providers and investigators will be blinded to treatment arm assignment.  
Clinical investigators will be blinded to identity of the group assignment (CCP1 or CCP2) that includes plasma with the higher neutralizing antibody end -point titer.  
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  
 
 
  
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   20 7.1 DISCONTINUATION OF STUDY  
Discontinuation of the study: The study sponsor, FDA , and IRB all have the right to terminate this study at any 
time.  
7.2 PARTICIPATION TERMINATION  
 
Participants will be considered terminated if:  
 consent was withdrawn  by the participant ,  
 the study Principal Investigator discontinues the parti cipant from study for severe lack of compliance,  
 or the participant  is lost to follow -up. 
 
7.3 PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY  
 
1. Participants can terminate study participation and/or withdraw consent at any time without prejudice.  
2. Randomized participants  who withdraw from the study will not be replaced.  If participant withdrawal 
occurs prior to plasma transfusion, the participant will have inad equate data, and therefore “new” 
replacement participants can be enrolled.   
3. The investigator may withdraw participants if the investigator determines that continued participation 
in the study would be harmful to the participant . 
4. Under certain circumstances, an individual participant’s receipt of CCP  will be prematurely or 
permanently discontinued. Specific events that will result in stopping a participant’s infusions in this study include:  
a. Failure to meet requirements established for safety  
b. Withdrawal from study  
c. Adverse event related to plasma administration  
d. Intercurrent illness that is not expected to resolve prior to the next scheduled transfusion which is assessed by the study PI or designee to require withdrawal of 2
nd transfusion.  
e. Clinically significant reaction associated to plasma transfusion.  
f. Death  
 If the study P I (or designee) decides that a participant should be withdrawn from further plasma transfusions , the 
protocol team must be alerted within 24 hours. All participants who di scontinue treatments should comply with 
protocol -specified visits and follow -up as required by the protocol and evaluation by the study PI (or designee). 
The only exception to this requirement is when a participant withdraws consent for all study procedure s. If a 
participant is withdrawn before completing the study, the reason for withdrawal must be documented appropriately in the study documents.  
 Premature Discontinuation of Evaluations  
For participants who begin but do not complete both plasma infusion s, the continued collection of virologic, 
immunologic, and other  samples will be determined on a case -by-case basis in discussion with the protocol team.  
The ability to complete virologic and immunologic endpoint analysis will be determined on a case -by-case basis in 
discussion with the protocol team.  
   
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   21 7.4 LOST TO FOLLOW- UP 
 
Participants classified as lost to follow -up (LTFU) need to meet both of the following criteria:  
 Failure to respond or reply to 3 documented phone contact attempts by the study staff, followed by  
 Failure to respond to a certified letter sent to the addre ss provided by the participant.  
Only after documentation of these failed attempts to connect with the participant, will they be determined to be LTFU . 
 
8 STUDY ASSESSMENTS AND PROCEDURES  
 
SAFETY AND OTHER ASSESSMENTS  
 
8.1 EFFICACY ASSESSMENTS  
 This section provides a general description of the procedures and assessments associated with this study.  
 
Informed Consent  
Prior to performing any study -related procedures or assessments, the investigator or study coordinator discusses 
the study with the poten tial participant (or their legally authorized representative) and obtains signed informed 
consent. This communication will be documented.  
 
Screening  
Screening for participant eligibility will be performed within 24 hours of hospital admission  to a COVID service  and 
within 24 hours of enrollment. Only those participants who meet all eligibility criteria specified in Section 5.1 Inclusion Criteria and Section 5.2 Exclusion Criteria will be enrolled. A unique PID will be assigned during the screening visit.   
Baseline and Enrollment  
Assign risk assessment (refer to p age 33)  and complete c linical status assessments using the WHO ordinal scale *, 
National Early Warning Score (NEWS) * [24], and SOFA * [29] at enrollment . Clinical status assessments will include 
calculations done at enrollment ( within 24 hours prior to plasma infusion ). Screening, enrollment , and 
randomization can occur on the same d ay provided eligibility criteria is met.  
As feasible, enrollment assessments will be performed by study coordinators or investigators. Given the nature of 
the COVID -19 pandemic, if hospital policies and/or PPE shortages prohibit in -person independent inves tigator 
physical exams and clinical status assessments, these parameters will be obtained by review of the electronic medical record (EMR).  
 *These illness severity assessment scales and scoring tools are described and available in the study -specific  
procedures . 
 
Randomization   
Participants will be r andomized to CCP1 or CCP2 at enrollment.   
 
CCP Transfusion  
Participants will be assessed on study Day 0 (pre -dose), and following transfusions per SOA (Section 1.3) while 
hospitalized and after discharge.       
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   22 Other Assessments 
 
• Physical Examination (PE). Will be recorded as documented in the EMR by clinical care team during 
hospitalization. The PE at the Day 28 tim epoint  will be completed by PI, co -investigator, primary care provider, 
or appropriately licensed study staff, when  possible.  
o Complete PE will include examination of skin, head, eyes, e ars, nose, throat, lymph nodes, heart, 
chest, lungs, abdomen, extremities, and neurologic system .  
o The PE information obtained from the EMR  (due to limitations imposed by COVID -19 restrictions) will 
be inclusive of system assessments as document ed in the EMR and may not include all the  
information listed above.  
 
• Medical History  
Significant medical history in most cases will be  obtained by the admitting physician  upon hospital  admission. 
All concurrent medical conditions in the last 30 days and any significant medical conditions (e.g., 
hospitalizations, surgeries, prior medical history) should be collected  as available in the p articipant’s medical 
record . Medical history obtained will include demographic information (e.g., date of birth, gender, race, and 
ethnicity, etc.), participant’s medical history, and medication history. This information can be obtained from the EMR as nec essary.  
Participants will be asked if they have any cultural or religious objections to receiving CCP during this 
assessment. 
 
• Concomitant Medications  
At enrollment, d ocument concomitant medications  taken by participant prior to hospitalization through EOS.  
These medications can be recorded from the EMR  and will i nclude the following:  
1. Prescription medications  
2. Over -the-counter medications  
3. Herbal treatments/nutritional supplements  
4. Blood products  
5. Prior and current receipt of medications used as therapies for COVID -19 
 
• Signs and Symptoms Assessments  
At entry, all signs and symptoms, regardless of grade, that occurred within the 2 weeks  before entry will be 
recorded  as medical history . Assessment of  adverse events (A Es) will be done at every study visit  after the first 
unit of CCP is transfused . Post -transfusion signs and symptoms, Grade ≥ 2, will be recorded. All signs or 
symptoms, definitely, possibly, or probably related to study interventions, will be recorded, regardless of grade. Information will be obtained from EMR$.  
 
• Treatment Emergent Adverse Events  
An event that first appears during treatment, which was absent before or which worsens relative to the pre -
treatment state.  
 
• Vital Signs  
Vital signs (weight  (as available), body temperature, pulse or heart rate, respiratory rate, and blood pressure) 
will be recorded according to the SO A and as recorded in the EMR . Repeat vital signs (EMR documented) may 
also be captured as necessary to elucidate the course of any untoward event or AE.  
 
• Electrocardiogram (ECG or EKG) – C ollect from EMR , if available and completed as part of hospital admission .  
  
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   23  
• Routine Clinical Procedures  
The study will collect the following information per SOA (Section 1.3) when done as part of clinical care  (and 
documented in EMR) . The study will collect these results as available in the medical record.  
o Radiographic or other imaging assessments. As performed for routine clinical care.  
o Clinical laboratory evaluations  for safety evaluation. Laboratory evaluations performed for routine 
clinical care  (reference SOA for laboratory values to be assessed). Safety and clinically relevant labs 
will be performed at UNC McLendon Laboratories.   
 
• Special Assays or P rocedures .  
Neutralization assays, antibody tit er by ELISA and SARS -CoV-2 PCR will be performed at participating research 
laboratories at UNC -Chapel H ill.   
 
• Optional Outpatient Longitudinal  Visits and Immunology  Resea rch Specimens  
Participants will be informed of the opportunity to  provide  optional immunology samples  and/or remain on 
the study through 6 months .  
 
Participant options include the following:  
1. Agree to the collection of optional samples during hospitalization and Day 28 only.   
2. Agree to optional outpatient visits on Days 49, 90, and 180 with the collection of optional samples . 
3. Refuse optional outpatient  visits and sample collections.  
 This option will collect samples at 5 timepoints  (Reference Study -Specific Laboratory Manual).  
The samples to be collected include:   
1. Blood samples  
a. The blood samples obtained will be used for measuring  primary and memory B-cell responses 
to SARS- CoV-2 and the trafficking and longevity of antibodies after CCP infusion.  
b. Collect these samples at Day s 0, 7, 28, 49, 90, and 180.  
i. Persons agreeing to optional sample collection, will have extra blood  collected (up to 
37 mL) at the Day 28 visit .  
2. Mucosal lining fluid samples  which include but are not limited to: nasal fluids (NP swab, and/or nasal 
epithelial lining strips (NELFS), oral fluids (saliva), intestinal ( stool) and /or resp iratory (endotracheal 
secretions).  
a. The NELF collection involve s the use of two absorbent filter paper strips placed into the nares 
and held there for 2 minutes. The mucosal samples will be used to study the trafficking of 
antibodies in CCP to primary site of SARS -CoV-2 infection.  
i. Collect at Days 0, 7, 49, 90, and 180 .  
b. The NP swab – collect only if participant agrees to the collection. Participant can refuse this 
sample and still be part of optional collections.  
i. Collect at Days 0 and 7.  
c. Saliva  
i. Collect at Days 0, 7, 49, 90, and 180 . 
d. Stool  
i. Collect if participant is able to provide sample or sample available at inpatient visits 
(Days 0 and 7) .  
ii. Collect at outpatient visits – provide participant with kit and directions for collection 
and storage of specimen prior to visits (Days 49, 90, and 180 ).   
 
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   24 All participants are required to complete the Day 28 visit (inpatient or outpatient)  and all samples will be 
collected  at th is visit (reference SOA). If unable to collect sample, document reason. Inability to collect sample 
or participant refusal to provide sample is allowed.  
 
There are  optional sample collections during the Day 0 and 7 inpatient visits; the optional outpatient visits and 
sample collections include Day s 49, 90 (3 month ), and 180 ( 6 month ).  The Day 28 collections are part of the 
main study and are not optional ; however, those participants providing consent for optional samples, will 
have extra blood collected at Day 28.   
 
Specimens generated from th ese optional immunology samples  will be analyzed in collaboration with other 
investigators.  
 
• End of Study Visit  
An End of Study (EOS) visit for the primary part of the study will occur at Day 28 .  Participants will complete 
the EOS visit per the SOA but will be followed as necessary for acceptable resolution of clinical events related 
to the study product.    
 
• Final or Last Study Visit  
The Final Study Visit may  occur approximately 6 months after the CCP infusion, depending on the participant 
consent to the optional outpatient visit as well as and can be based on the  duration and severity of any 
ongoing, treatment related AEs. An individual participant will be con sidered to have completed the study if 
the participant was followed through their last protocol- specified visit/assessment. Participants who have a 
new clinical event related to the CCP  will be followed on study until the clinical event is resolved or deemed 
stable and irreversible.  
 
• Biospecimens  
Biospecimens will be those obtained by the study for research purposes in addition to those collected as part of routine clinical care. All biospecimens will be used to address the aims of the study. The research assays will be collected from admission (when available) and at the research visits (per SOA, section 1.3). Research assays will be processed and stored in associated research laboratories. Additional details on collection, processing, storage, and shipping of laboratory samples will be provided in the Study Specific Manual.  Appropriate 
selection and timely collection of high- quality specimens, proper storage procedures , and comprehensiv e 
diagnostic testing will ensure the quality of data.  Appropriate selection and timely collection of high -quality 
specimens, proper storage procedures , and comprehensive diagnostic testing will ensure the quality of data.  
Biosafety procedures will be as per local policy/guidance, in keeping with national and/or international 
regulations, and will be applied to the collection, storage, transfer, and laboratory handling of research 
samples.
 
 
8.2 SAFETY AND OTHER ASSESSMENTS  
All clinical and laboratory information required by this protocol will be obtained from clinical testing done as part of routine clinical care. Some protocol indicated evaluations, not assessed as part of clinical care will be added on the labs drawn , when possible  and requested by t he PI . Otherwise, these labs will be documented as unobtained. 
We will not list these as protocol deviations as the severity of illness and SOC restrictions/isolation procedures resulting from COVID -19 infection prohibits additional PPE and possibly additional blood draws. All protocol 
required procedures will be in the source documents . 
 
Clinical Procedures for Safety  
• Plasma Administration  
Plasma will be obtained and administered per Institutional standard operational policies and procedures.  
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   25 • Post Infusion Management  
Participant will be managed per Institutional standard operational policies and procedures.  
 
8.3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS  
8.3.1  DEFINITION OF ADVERSE EVENTS (AE)  
 
Common Terminology Criteria for Adverse Events (CTCAE ) Terms  
An Adverse Event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medical treatment or procedure that may or 
may not be considered related to the medical treatment or procedure. An AE is a term that is a unique representation of a specific event used for medical documentation and scientific analyses. Each CTCAE v4.0 term is a MedDRA LLT (Lowest Level Term). . 
 
8.3.2  DEFINITION OF SERIOUS ADVERSE EVENTS (SAE)  
 Any adverse event that results in any of the following outcomes:  
1. Death  
2. Life-threatening (immediate risk of death)  
3. Prolongation of existing hospitalization  
4. Persistent or significant disability or incapacity  
5. Important medical events that may not result in death, be life threatening, or require intervention or 
escalation of care may be considered a serious adverse event when, based upon  appropriate medical 
judgment, they may jeopardize the subject and may require medical or surgical intervention to 
prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive trea tment in an emergency room or at home, blood dyscrasias , or 
convulsions that do not result in inpatient hospitalization.  
 
8.3.3  CLASSIFICATION OF AN ADVERSE EVENT  
 Grading of study adverse events will be assessed using CTCAE grading scale developed by N ational Cancer 
Institute (NCI) , National Institutes of Health (NIH) , https://evs.nci.nih.gov/ftp1/CTCAE/About.html  
8.3.3.1  SEVERITY OF EVENT  
The determination of seriousness, severity, and causality will be made by an on- site investigator who is 
qualified (licensed) to diagnose adverse event information, provide a medical evaluation of adverse events, and classify adverse events based upon medical judgment. This includes but is not limited to physicia ns, physician assistants, and nurse practitioners.  All AEs will be assessed by the study clinician 
using a CTCAE  grading system . 
 
1. Grade 1 or Mild : asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.   
2. Grade 2 or Moderate: minimal, local or noninvasive intervention indicated; limiting age -appropriate 
instrumental ADL*.   
3. Grade 3 or Severe or medically significant but not immediately life -threatening; hospitalization or 
prolongation of hospitalization indicated; disabling; limited self care ADL**  
4. Grade 4 or Life -threatening ; urgent intervention indicated.  
5. Grade 5 or Death related to AE  
 
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   26 *Instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, managing 
money, etc.  
**Self care ADL refer s to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and 
not bedridden.  
 
8.3.3.2  RELATIONSHIP TO STUDY INTERVENTION  
All adverse events (AEs) must have their relationship to study intervention assessed by the clinician who 
examines and evaluates the participant based on temporal relationship and his/her clinical judgment. The degree of certainty about causality will be g raded using the categories below.  
 
1. Definitely Related – There is clear evidence to suggest a causal relationship, and other possible 
contributing factors can be ruled out. The clinical event, including an abnormal laboratory test result, occurs in a plausible time relationship to study intervention administration and cannot be explained by concurrent disease or other drugs or chemicals. The response to withdrawal of the study intervention (dechallenge) should be clinically plausible. The event must be phar macologically or phenomenologically definitive, with use of a satisfactory rechallenge 
procedure if necessary. 
2. Probably Related – There is evidence to suggest a causal relationship, and the influence of other 
factors is unlikely. The clinical event, including an abnormal laboratory test result, occurs within a reasonable time after administration of the study intervention, is unlikely to be attributed to concurrent disease or other drugs or chemicals, and follows a clinically reasonable response on withdraw al (dechallenge). Rechallenge information is not required to fulfill this definition.  
3. Potentially Related – There is some evidence to suggest a causal relationship (e.g., the event 
occurred within a reasonable time after administration of the trial medicat ion). However, other 
factors may have contributed to the event (e.g., the participant’s clinical condition, other concomitant events). Although an AE may rate only as “possibly related” soon after discovery, it can be flagged as requiring more information and later be upgraded to “probably related” or “definitely related ,” as appropriate.  
4. Unlikely to be related – A clinical event, including an abnormal laboratory test result, whose 
temporal relationship to study intervention administration makes a causal re lationship improbable 
(e.g., the event did not occur within a reasonable time after administration of the study intervention) and in which other drugs or chemicals or underlying disease provides plausible explanations (e.g., the participant’s clinical cond ition, other concomitant treatments).  
5. Not Related – The AE is completely independent of study intervention administration, and/or 
evidence exists that the event is definitely related to another etiology. There must be an alternative, definitive etiology do cumented by the clinician.  
 
8.3.3.3  EXPECTEDNESS   
The investigators will be responsible for determining whether an adverse event (AE) is expected or unexpected.  An AE will be considered unexpected if the nature, severity, or frequency of the event is not consistent with the risk information previously de scribed for the study intervention . 
8.3.4  TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP 
The occurrence of an adverse event (AE) or serious adverse event (SAE) may come to the attention of study personnel during study visits and interviews of a stu dy participant presenting for medical care, or 
upon review by a study monitor.  
 
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   27 Any medical condition that is present at the time that the participant is screened and prior to the CCP 
transfusion will be considered baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any time after receipt of the study product, it will be recorded as an AE.  
 Given the nature of severity of the underlying illness, participants will have many symptoms and abnormalities in vital signs and laboratory values. AEs and SAEs will be documented following the first administration of CCP.  All Grade 3 and 4 AEs will be r ecorded in the database  in this trial. In addition, the 
following AEs will be reported:  
1. All AEs (≥ Grade 2) and SAEs
 resulting from study product administration will be documented and 
followed until resolution even if AEs extend beyond the study -reporting period.  
2. All AEs including local and systemic reactions related to the CCP transfusion but not meeting the criteria for SAEs will be documented.  
3. Any AEs leading to do se modification.  
 Intermittent abnormal laboratory values or vital sign measurements common  in the severely ill 
populations (such as electrolyte abnormalities, low blood pressure, hyperglycemia, etc.) that are part of the same clinical diagnosis (e.g., uncontrolled diabetic) can be recorded once with the worst grade for each adverse event , with the start and stops dates of the intermittent syndrome. If there is clear 
resolution of the event, and then recurrence, it should be treated as a separate adverse event.  
 Resolution of an adverse event is defined as the return to pre- treatment status or s tabilization of the 
condition with the expectation that it will remain chronic. At any time after completion of the study, if the investigator becomes aware of a SAE that is suspected to be related to study product, incident will be investigated and report ed as required .  
 IInformation to be collected includes event description, time of onset, clinician’s assessment of severity, 
relationship to study product (assessed only by those with the training and authority to make a diagnosis), and time of resolution/stabilization of th e event. All CCP -related AEs will be followed to adequate 
resolution.  
 
AE assessment during the optional outpatient visits will be documented only as they relate to the outpatient study procedures and events. All other medical events related to medical his tory will be 
recorded as medical history and not as an adverse event.  
 
8.3.5  ADVERSE EVENT REPORTING  
Reporting will only be required for adverse events judged to be potentially or definitely related to the administration of the CCP.  
 Events will be reported starting with the start date of the first transfusion through Day 21 while hospitalized. No AE assessment will be required after participant discharge, unless previously reported and being followed through resolution.  
 
 
8.3.6  SERIOUS ADVERSE EVENT REPORTING  
Reporting will only be required for serious adverse events judged to be potentially or definitely related to the administration of the CCP.  
 All SAEs will be documented from the first administration of study product  through Day 21. (Reference 
section 8.3.5)  
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   28  
The PI (or designee)  will immediately report to the sponsor any serious adverse event, considered to be 
potentially related to the study intervention , and will include an assessment  indicating a reasonable 
possibility that the study intervention caused the event. Study endpoints that are serious adverse events (e.g., all -cause mortality) must be reported in accordance with the protocol unless there is evidence 
suggesting a causal relationship between the study intervention and the eve nt (e.g., death from 
anaphylaxis). In that case, the investigator must immediately report the event to the sponsor.  
 All study -related serious adverse events (SAEs) will be followed until satisfactory resolution or until the 
site investigator deems the event to be chronic or the participant is stable. Other supporting documentation of the event may be requested by the  US Food and Drug Administration (FDA) or study 
sponsor and should be provided as soon as possible.  
 The study PI sponsor will be responsible for notifying the FDA of any unexpected fatal or life -threatening 
suspected adverse reaction potentially related to the study product as soon as possible, but in no case later than 7 calendar days after the PI initial receipt of the information.  In additi on, the study PI must 
notify FDA and all participating investigators in an Investigational New Drug (IND) safety report of potential serious risks, from clinical trials or any other source, as soon as possible, but in no case later than 15 calendar days af ter the sponsor determines that the information qualifies for reporting.  
 
8.3.7  REPORTING EVENTS TO PARTICIPANTS  
We would inform all study participants by letter or electronic messaging of any AEs determined by the  
Safety Monitoirng Committee to merit such noti ce.  
8.4 NEW SAFETY INFORMATION  
 
8.4.1  DEFINITION OF NEW SAFETY INFORMATION (NSI)  
The Office for Human Research Protections ( OHRP) considers NSI  involving risks to participants to include, 
in general, any incident, experience, or outcome that meets all of the following criteria:  
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are described in the protocol -related documents, such as the Institutional Review Board (IRB) -
approved research protocol and informed consent document; and (b) the characteristics of the participant population being studied;  
• Related or possibly related to participation in the research (“possibly related” means there is a reasonable possibility that the incident, experience, or outcome may have b een caused by the 
procedures involved in the research); and  
• Suggests that the research places participants or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized.  
 
8.4.2   NEW SAFE TY INFORMATION  REPORTING  
The investigator will report any unanticipated NSIs related to the study product  to the UNC Institutional 
Review Board (IRB) and the North Carolina Translational and Clinical Sciennces Institute (NC TraCS) Data 
and Safety Monitoring Board (DSMB). The NSI report will include the following information:  
• Protocol identifying information: protocol title and number, PI’s name, and the IRB study  number ; 
• A detailed description of the event, incident, experience, or outcome;  
• An explanation  of the basis for determining that the event, incident, experience, or outcome 
represents an NSI ;  
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   29 • A description of any changes to the protocol or other corrective actions that have been taken or 
are proposed in response to the NSI . 
 NSI will be reported per the UNC IRB SOP for NSI reporting.  
 
8.4.3  REPORTING NEW SAFETY INFORMATION  TO PARTICIPANTS  
We would inform all study participants by letter or electronic messaging of any new safety information  if 
it is determined by the UNC IRB to merit such notice.  
9 STATISTICAL CONSIDERATIONS  
9.1 STATISTICAL HYPOTHESES  
For the primary aim of assessing safety we will not perform any statistical testing. Analysis of adverse event data 
will primarily be  descriptive.  We anticipate that high and standard titer anti- SARS -CoV-2 convalescent plasma will 
be well tolerated.  
 For the primary aim of assessing efficacy of high versus low titer anti- SARS- CoV-2 convalescent plasma, o ur 
primary hypothesis is that by providing hig h-titer anti -SARS- CoV-2 plasma, the duration of hospitalization will 
decrease as compared to the group receiving standard- titer plasma.  
 
9.2 SAMPLE SIZE DETERMINATION  
The primary analysis will be done on a planned sample size of  56 participants,  randomized in a 1:1 ratio to receive 
high -titer anti -SARS- CoV-2 convalescent plasma versus standard- titer CCP. Sample size estimation was based on 
having sufficient power to detect a clinically meaningful difference in time to hospital discharge comparing  
patients randomized to high versus low titer anti- SARS -CoV-2 convalescent plasma.  
 For estimating sample size we tested the null hypothesis that a hazard ratio of high versus standard titer CPP was equal to 1, versus the alternative hypothesis that the h azard ratio of high versus standard titer CPP was not equal 
to 1. We assumed a median time to discharge of 14 days for the low titer group, a 0.01 probability of death during hospitalization and a pre -specified two -sided significance level of 0.05. With an  anticipated enrollment for initial 
analysis of N=2 8 in each arm, N=56 total enrollment, we will have 80% power to detect a hazard ratio of 2.25 for 
time to discharge, corresponding to a probability of remaining hospitalized at Day 14 post -infusion of 0.50  for the 
low titer CPP group, and 0.21 for the high titer CPP group. Our power increases to 0.92 with increasing difference in probability of remaining hospitalized at D ay 14 post -infusion of 0.35. Given uncertainty of hospitalization length 
of stay, inpatient mortality, and expected efficacy of high versus low titer CPP, we will actively monitor outcomes 
with ongoing accrual.  
 
9.3 POPULATIONS FOR ANALYSES  
• Primary analysis: Intention -to-Treat (ITT) with 2 units of CCP  
• Exploratory  analys es: Per-protocol analysis of CCP who received both doses prior to admission to ICU  
 
9.4 STATISTICAL ANALYSES  
 
9.4.1  SAFETY ANALYSES  
Analysis of AE data will primarily be descriptive based on MedDRA coding of events. AE data will be 
compared between randomized arms using Fisher’s Exact Test.  
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   30 For the safety endpoint, we will describe all study treatment -related AEs through the end of stu dy 
approximately 24 weeks after getting their first infusion at Day 0. AEs will be coded to the Medical 
Dictionary for Regulatory Activities (MedDRA). Events prior to treatment (e.g., due to study -related 
procedure s) will be listed separately in an appendi x to the final clinical study report . The following tables 
of AE data will be created to summarize the number and percent of participants who experience at least 
one event of each of the following types:  
• All AEs  
• CCP-related AEs by severity grade  
• AEs by sev erity grade  
• All SAEs (this may be a listing if there are few events)  
• CCP-related SAEs  
• Fatal AEs (this may be a listing if there are few events)  
• AEs that result in study discontinuation  
• AEs that lead to withdrawal of study product  
• AEs with severity grade 3 or greater  
• CCP-related AEs with severity grade 3 or greater  
 
All of these tables will display the number and percent of participants that experience the given event and 
will display events by System Organ Class (SOC) and Preferred Term (PT). Events will be displayed alphabetically for SOC and in descending order of overall PT incidence within each SOC.  
 
9.4.2  GENERAL APPROACH  
Statistical Analysis:  Exploratory analyses are planned to evaluate pre -specified factors relevant to CPP 
administration, clinical co urse , and outcomes. Analyses will be intention -to-treat (ITT), with patients 
analyzed in their assigned arms regardless of compliance with the interventions. In addition to primary ITT analysis, we will conduct analyses that explore corrections for compliance with the interventions such as 
dose reduction (receiving only 1 unit instead of 2 due to a transfusion reaction after the first dose) in both 
arms to supplement ITT analyses with information on the actual intervention exposure while retaining the valid ity of the randomization- based inference. Categorical data will be presented in the form of 
frequencies and percentages. Continuous data will be provided with descriptive statistics, including mean, standard deviation, median, interquartile range, and full range. Ordinal data will be presented in the form 
of frequencies, median, and percentiles. We will use SAS version 9.4 or R version 4.0.0 for all analyses.  
 Tests of Hypotheses:   Analyses of dichotomous outcomes by arm will be tested using a Chi -square te st for 
proportions. As indicated, we will use nonparametric statistics including Fisher’s exact test to test for differences in proportions. Analyses of continuous outcomes by arm will be tested using t -tests, with the 
nonparametric alternative of Mann -Whitney U test used as indicated. For continuous outcomes we will 
assess normality, and as indicated rely on nonparametric tests. Additionally , we will consider re -
parametization and transformation based on the underlying distribution. Analyses of ordinal out comes by 
arm will be tested using the Wilcoxon test.  
 The difference in proportions will also be calculated as a measure of effect for dichotomous outcomes. For continuous outcomes, the difference in means  or a nonparametric equivalent  will be calculated as a 
measure of effect. The summary measure of effect for ordinal outcomes will be an odds ratio estimated using an ordinal logistic model. For all measures of effect we will calculate 95% confidence limits  as 
measures of precision. For time to event analyses we will plot Kaplan -Meier curves and use the log -rank 
test to test for differences in time to event. Kaplan -Meier event rates at various time points with 2 -sided 
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   31 confidence intervals will be summarized.  In addition, Kaplan -Meier estimates of quartiles (median, 25th 
and 75th percentiles) with 2 -sided 95% confidence intervals will be calculated if applicable. All tests will 
be 2 -sided with a pre -specified alpha of 0.05.  
 
Given the rapidly evolving COVID -19 pandemic , we are prepared to accommodate new knowledge and 
information and modify our proposed approach and analyses as indicated.  
 
9.4.3  ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S)  
 
Event times for discharge from the hospital will be obtained in continuous time (days) from time 0 (day of 
infusion) until the first of date of hospital discharge or date when the patient was last at risk (right censoring time, including date of death). Our primary analysis will use the standard Kaplan -Meier 
estimate of the survival or cumulative incidence function. An unadjusted log- rank test will be used to test 
for differences between treatment groups. The proportional hazards regression model will be used to adjust for risk (high versus average risk), age (in years), sex, ABO type, levels 2 -5 on the WHO ordinal 
outcome scale, and time from symptom onset in days, all measured at time 0. Cox proportional hazards regression models will be used to estimate unadjusted and adjusted hazard ratio s as measures of effect, 
and 95% confidence intervals as measures of precision. We will assess model fit of the Cox model using log likelihood statistics and the proportionality assumption will be assessed relying on graphical analyses and statistical test ing. If tests of the proportional hazards assumption do not apply, inferences will be 
obtained using robust sandwich estimators of standard error. Additionally, we may use alternate models, such as the proportional odds model, transformations of covariates  may be considered or time effects 
may be included in the model.  
 
A Cox proportional hazards model with right censoring on death has a valid interpretation as the effect of the treatment assignment on the cause- specific hazard function for the event discharge from hospital. 
However, death prior to hospital discharge may be considered a competing risk, and treating deaths as right censoring may not be appropriate. In this case we will estimate the cumulative incidence of hospital discharge adjusting for the  incidence of mortality. We anticipate a high level of completeness of data; 
however , in the event of missing data we will rely on stochastic multiple -imputation to account for 
missingness. Multiple -imputation provides unbiased estimates of the treatment effect and yields 
appropriate precision if data are missing completely at random, or under the weaker assumption that data are missing at random conditional on measured variables.  
 
9.4.4  SUB -GROUP ANALYSES  
At the time of randomization, participants will be assig ned to a clinical severity as floor status versus ICU 
status as determined by the treating physician. The primary analysis will include all participants. In the 
sub-group analysis, floor status participants will be analyzed separately from ICU status parti cipants.  
 
9.4.5  EXPLORATORY ANALYSES  
For exploratory analyses, logistic regression will be used to model dichotomous outcomes. For continuous outcomes we will use ordinary least squares regression and non -linear mixed models for modeling outcomes 
that are rare as indicated. For time to event analyses we will use proportional hazards models. All models will be adjusted for risk (high versus average risk as indicated below), age (in years), sex, levels 2 -5 on the WHO 
ordinal outcome scale, and time from symptom onset in days, all measured at time 0. Adjusted measures of effect will be used as indicators of effect size and 95% confidence intervals as indicators of precision.  
 
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   32 • Change in WHO ordinal clinical status scale while hospitalized and at Day 28: For the efficacy endpoint of 
the WHO COVID scale on each day of hospitalization beginning on day 0 (pre -infusion) and through D ay 
28, we will compute probabilities related to the comparison of high versus standard titer CPP. The 
summary efficacy parameter will be an odds ratio (OR) from an ordinal logistic model, with OR>1 being favorable to high titer versus low titer when the ordinal WHO scale ranges from 1=death to 8=no evid ence 
of infection. For the ordinal outcome scale, the proportional odds (PO) ordinal logistic semiparametric model is an ideal approach as it allows the distribution across the levels to be arbitrary. In addition to the dichotomous treatment assignment var iable, the PO model will be adjusted for baseline risk factors (high 
versus average risk as indicated below), age (in years), sex, levels 2 -5 on the WHO ordinal outcome scale, 
and time from symptom onset in days, all measured at time 0.  
 
• Change in National Early Warning Score (NEWS) while hospitalized and at D ay 28 (linear regression)  
 
• Days of supplemental oxygen, NIV/high -flow oxygen, mechanical ventilation/ECMO while hospitalized 
and at D ay 28 (linear regression)  
 
• Mortality at Day 28: (logistic regression )  
High risk:  
• WHO ordinal clinical status >4 or  
• ordinal scale ≤ 4 with any one of the following  
• ≥60 years or age  
• immunocompromise (immunosuppressive drugs, solid tumor, solid organ transplant, hematologic 
malignancies, hematologic stem cell transplantation, rheumatological disease on 
immunosuppressants, inflammatory bowel disease on immunosuppressants, asthma or COPD on chronic stero id therapy, HIV+ with CD4 count <200 cells/µl ) 
• diabetes mellitus  
• obesity  
• uncontrolled hypertension  
• cardiovascular disease  
• chronic pulmonary disease  
 
Average risk: <60 years of age AND absence any of the above high -risk factors  
 
• Analysis of the anti- SARS- CoV-2 titers  
Analysis of titers will primarily be descriptive, comparing the geometric mean titers (total antibody, antigen -
specific, and neutralizing antibody) at Days 0, 3 (+/ -1 day) , 7 (+/ -1 day or at discharge), 21, 28 , and at months 
3 and 6 between the randomized arms. It is also of interest to describe the entire distributions of anti- SARS-
CoV-2 titers by randomized arms and contrast these distributions. Therefore, we will use quantile regression 
to describe whether there is a shift or change in the titer distribution between randomized arms. Given that repeated measures of titers will be obtained, we will account for the correlation in measures within individuals using a cluster bo otstrap in order to properly estimate the p -value and 95% confidence intervals.  
 
• Analysis of the rates, levels , and duration of SARS -CoV-2 RNA in NP swabs and other body fluids  
This exploratory analysis will be primarily descriptive. The proportion positive at Days 0, 3, 7, 21 , and 28 days 
and whether individuals lose positive status at a subsequent time. To determine the proportion that are 
positive, we will do a pooled complementary log -log model in order to describe the cumulative incidence of 
SARS- CoV-2 positivity over time. The pooled complementary log- log model is a discrete time -to-event -analysis 
that estimates the log hazard rate at each discrete time point. Like the analysis of anti- SARS- CoV-2 titers, the 
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   33 goal of this secondary aim is to describe the distribution of SARS -CoV-2 RNA between randomized arms. 
Therefore, we will use the same approach as for the anti- SARS- CoV-2 titers. Because the exact day that an 
individual becomes negative is not known, a minimum and maximum amount of positive time will be used to 
describe the positive duration of each individual. If the sample is adequate, we will describe the duration of positivity using a non -parametric approach for time -to-event analysis.  
 
• Other biomarkers  
Testing  results available through routine clinical care : CBC, differential, PT/INR, PTT, d- dimer, fibrinogen, 
albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, LDH, phosphorus, potassium, total protein, AST, ALT, sodium, C -reactive protein,  and IL-6 on Days 0, 1, 3 (+/-1 day) , 
6 (+/ -1 day), 7 (or day of discharge) , 14, 21, and 28. We will use the same approach as above.  
  
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS 
 
10.1 REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS  
 
10.1.1 INFORMED CONSENT PROCESS  
 
10.1.1.1  CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO PARTICIPANTS  
Consent forms describing in detail the study intervention, study procedures, and risks are given to the participant (and/or legally authoriz ed representative) and written documentation of informed consent is 
required prior to starting any study procedures and study intervention/administering study intervention.   
 
10.1.1.2  CONSENT PROCEDURES AND DOCUMENTATION  
All participants will be consented, either in person or using virtual options per UNC -CH IGHID Regulatory 
Standard Operating Procedure (SOP). The study can use Adobe Sign for consenting remotely and securely.  
The study team member will review the consent(s) with the potential participant over the phone after emailing them the password protected consent(s). Potential participants meeting eligibility criteria will be invited by the study team member to participate in the study. If participants express an interest in the study, the study will be expla ined in detail by a study team member during a telephone meeting or in 
person. If the participant agrees to participate in the study, they will electronically sign the study consent form(s) if done remotely or sign in writing if done in person.    
10.1.2  STUDY D ISCONTINUATION AND CLOSURE  
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause.  Written notification, documenting the reason for study suspension or termination, will be provided by the suspending or terminating party to the Investigational New Drug (IND sponsor and regulatory authorities.  If the study is prematurely terminated or suspended, the Principal Investigator (PI) will promptly inform study participants, the Institutional Review Board (IRB), and funding sponsor and will  
provide the reason(s) for the termination or suspension.  Study participants will be contacted, as 
applicable, and be informed of changes to study visit schedule.  
  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Demonstration of efficacy that would warrant stopping    
• Insufficient compliance by participant to protocol requirements  
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   34 • Data that are not sufficiently complete and/or evaluable  
• Determination that the primary endpoint has been met  
• Determination of futility  
 
Study may resume once concerns about safety, protocol compliance, and data quality are addressed, and 
satisfy the funding sponsor, IRB , and/or  FDA.  
 
Halting Criteria for the Study: The study enrollment and study treatment will be stopped and an ad hoc 
review will be performed if any of the specific following events occur or, if in the judgment of the study 
physician, participant safety is at risk of being compromise d: 
 1. Death within one hour of plasma infusion  
 2. Occurrence of a life -threatening allergic/hypersensitivity reaction (anaphylaxis), manifested by 
bronchospasm with or without urticaria or angioedema requiring hemodynamic support with pressor 
medications or mechanical ventilation, TRALI, TACO  
 
3. One participant with a study product -related SAE.  
 4. Two participants with a Grade  3 or higher lab toxicity for the same parameter associated with study 
product. (Grading will be assessed using Common Terminology Crite ria for Adverse Events (CTCAE) 
grading scale developed  by NCI, NIH , https://evs.nci.nih.gov/ftp1/CTCAE/About.html ) 
 5. An overall pattern of symptomatic, clinical, or laboratory events that the Safety Monitoring Committee consider s associated with study product and that may appear minor in terms of individual 
events but that collectively may represent a serious potential concern for safety.  
 6. Any other event(s) which is considered to be a serious adverse event in the good clinical judgment of the responsible physician. This will be appropriately documented.  
 
10.1.3 CONFIDENTIALITY AND PRIVACY  
Participant confidentiality and privacy is strictly up held . This confidentiality is extended to cover testing of 
biological samples and genetic tests in addition to the clinical information relating to participants.  
Therefore, the study protocol, documentation, data, and all other information generated will be held in 
strict confidence. No information concerning the study or the data will be released to any unauthorized third party without prior written approval of the IND spons or.  
 
All research activities will be conducted in as private a setting as possible.  
 The study monitor, other authorized representatives of the funding sponsor, representatives of the IRB,  
or other regulatory agencies may inspect all documents and records  required to be maintained by the 
principal investigator, including but not limited to, medical records (office, clinic, or hospital) and 
pharmacy records for the participants in this study. The clinical study site will permit access to such records.  
 The study participant’s contact information will be securely stored at  the clinical study site for internal use 
during the study. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by the reviewing IRB, Institutional policies, or sponsor requirements.  
 
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   35 Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be 
transmitted to and stored in the UNC School of Medicine secure server . This will not include the 
participant’s contact or identifying information. Rather, individual participants and their research data will be identified by a unique study identification number. The study data entry and study management systems used by clinical sites and b y research staff will be secured and password protected. At the end of 
the study, all study databases will be de -identified and archived.  
 
10.1.4 FUTURE USE OF STORED SPECIMENS AND DATA  
 
With the participant’s approval and as approved by local Institutional Review Boards (IRBs), de -identified 
biological samples will be stored at the Shannon Wallet and Aravinda de Silva Laboratories  for up to 5 
years .  These samples could be used to research the effectiveness of neutralizing antibodies against SARS -
2, antibody -dependent enhancement of COVID -19 and its complications and other conditions for which 
individuals with COVID -19 are at increased risk, and to improve t reatment. The Shannon Wallet and 
Aravinda de Silva Laboratories will also be provided with a code -link that will allow linking the biological 
specimens with the phenotypic data from each participant, maintaining the blinding of the identity of the particip ant. 
 During the conduct of the study, an individual participant can choose to withdraw consent to have biological specimens stored for future research. However, withdrawal of consent with regard to biosample storage may not be possible after the study is completed.  
 
When the study is completed, access to study data and/or samples will be provided through the Principal Investigator.  
 
10.1.5 KEY ROLES AND STUDY GOVERNANCE  
Provide the name and contact information of the Principal Investigator  
Principal Investigator  Co-Principal Investigator  
Luther Bartelt, MD  David Margolis, MD  
University of North Carolina at 
Chapel Hill  UNC -Chapel Hill School of 
Medicine   
7314A Medical Biomedical 
Research Building  
120 Mason Farm Rd., CB 7032 University of North Carolina at Chapel Hill  
Chapel Hill, NC 27599 -7032  2016 Genetic Medicine Building 
120 Mason Farm Rd., CB 7042 University of North Carolina at Chapel Hill  
Chapel Hill, NC 27599 -7042 
919-966-6152  919-966-6388  
luther_bartelt@med.unc.edu  dmargo@med.unc.edu   
 
10.1.6 SAFETY OVERSIGHT  
Safety oversight will be under the direction of the NC TraCS DSMB. The NC TraCS DSMB will serve as the 
Independent Safety Monitoring Committee , composed of ndividuals with the appropriate expertise,  
including infectious diseases and pulmonary specialists, without conflict of interests, will be established. Members should be independent from the study conduct and free of confl ict of interest, or measures 
should be in place to minimize perceived conflict of interest.  The DSMB will meet at least every 6 months 
to assess safety and efficacy data on each arm of the study. In addition, should any grade 3 or higher AEs, 
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   36 SAEs , or dea ths occur, these will be reported to the DSMB immediately.  Reports from DSMB meetings and 
recommendations by the DSMB will be provided by the study team to the FDA and the IRB. 
 
10.1.7 CLINICAL MONITORING  
To ensure the safety of participants in the study, compliance with applicable regulations, and to ensure 
accurate, complete, and reliable data, the study PI will keep records of laboratory tests, clinical notes, and participant medical records in the participant files as source documents for the study.  
 An independent study monitor will monitor the study on a regular basis throughout the study period 
according to the study monitoring plan. The study monitor periodically will conduct a review of a sample 
of the participant data recorded on source documents at the study site. The study PI and site study personnel must address all queries in a timely manner.  
 Participation as an Investigator in this study implies acceptance of the potential for inspection by the study Sponsor/Funder and its Representatives, US or non -US government regulatory authorities, IRB, and 
applicable compliance and quality assurance offices. The study PI (or designee) will permit study -related 
audits and inspections and will provide access to all study -related documents (e.g., source documents, 
regulatory documents, data collection instruments, study data, etc.). The study PI will ensure the capability for inspections of applicable study -related facilities (e.g., IDS pharmacy, CTRC, etc.).  
 
Minimizing risk to participants  
Procedures to minimize r isk to participants in the conduct of this study include: 1) informing participants 
about risks so they can recognize and report harms in partnership with the study team; 2) respecting local/national blood draw limits; 3) direct observation of participants  after study treatment administration 
with CCP and collection of information regarding side effects for several days post product administration; 4) having study staff properly trained in administering study procedures that may cause physical harm or psychologic distress, such as blood draws and infusions; and 5) providing study monitoring as applicable . 
 
10.1.8 QUALITY ASSURANCE AND QUALITY CONTROL  
The clinical study site will perform internal quality management of study conduct, data and biological 
specimen collection, documentation , and completion.  The site will have a  quality management plan 
describ ing their quality management.  
 
Quality control (QC) procedures will be implemented beginning with the data entry system and data QC 
checks that will be  run on the database will be generated. Any missing data or data anomalies will be 
communicated to the study site(s) for clarification/resolution.  
 Following written Standard Operating Procedures (SOPs), the monitors will verify that the clinical trial is conducted and data are generated and biological specimens are collected, documented (recorded), and reported in compliance with the protocol, International Conference on Harmonisation Good Clinical Practice (ICH GCP), and applicable regulatory requirements  (e.g., Good Laboratory Practices (GLP), Good 
Manufacturing Practices (GMP)).  
 The investigational site will provide direct access to all trial- related activities , source data/documents, and 
reports for the purpose of monitoring and auditing by the funding sponsor, and inspection by local and 
regulatory authorities.  
   
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   37  
  
 
10.1.9 DATA HANDLING AND RECORD KEEPING  
 
10.1.9.1  DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  
The clinical research staff is responsible for data collection under the supervision of the site PI  (or 
designee). The study PI (or designee) is responsible for ensuring the accuracy, completeness, legibility, 
and timeliness of the data reported.  
All sourc e documents should be completed in a neat, legible manner to ensure accurate interpretation of 
data.   
Hard copies of the study visit worksheets will be provided for use as source document worksheets for 
recording data for each participant enrolled in the study.  Data recorded in the electronic case report form derived from source documents should be consistent with the data recorded on the source documents.  
Clinical data (including adverse events (AEs), concomitant medications, and expected adverse reactions data) and clinical laboratory data will be entered into a UNC School of Medicine Database, a 21 CFR Part 11-compliant data capture system. The data system includes password protection and external quality 
checks, to identify data that appear inconsiste nt, incomplete, or inaccurate. Clinical data will be entered 
directly from the source documents.  
 
10.1.9.2  STUDY RECORDS RETENTION  
Study documents should be retained for a minimum of 2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or until at least 2 years have elapsed since the formal discontinuation of clinical development of the study intervention. These documents should be retained for a longe r period, however, if required 
by local regulations. No records will be destroyed without the written consent of the sponsor, if 
applicable. It is the responsibility of the sponsor to inform the investigator when these documents no 
longer need to be retain ed. 
 
10.1.10  PROTOCOL DEVIATIONS  
A protocol deviation is any noncompliance with the clinical trial protocol, International Conference on Harmonisation Good Clinical Practice (ICH GCP), or Study Specific Procedures Manual  requirements. The 
noncompliance may be eit her on the part of the participant, the investigator, or the study site staff. As a 
result of deviations, corrective actions are to be developed by the site and implemented promptly.  
 
These practices are consistent with ICH GCP:  
• 4.5 Compliance with Proto col, sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.20 Noncompliance, sections 5.20.1, and 5.20.2.  
 
It is the responsibility of the site principal investigator to use continuous vigilance to identify , documen t, 
and report protocol deviations . All protocol deviations must be addressed in study source documents and 
reported to UNC IRB per their reporting requirements . The site principal investigator is responsible for 
knowing and adhering to the reviewing IRB requirements.  
 
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   38 10.1.11  PUBLICATION AND DATA SHARING POLICY  
This study will be conducted in accordance with the following publication and data sharing policies and 
regulations:  
• NIH Public Access Policy, which ensures that the public has access to the published results of NIH -
funded research. It requires scientists to submit final peer- reviewed journal manuscripts that arise 
from NIH funds to the digital archive PubMed Central  upon acceptance for publication.  
• NIH Data Sharing Policy and Policy on the Dissemination of NIH- Funded Clinical Trial Information 
and the Clinical Trials Registration and Results Information Submission rule. As such, this trial will 
be registered at ClinicalTrials.gov, and results information from this trial will be submitted to 
ClinicalTrials.gov, if required.  
• NIH Genomic Data Sharing Policy, which applies to all NIH -funded research that generates large -
scale human or non -human genomic data, as well as the use of these data for subsequent 
research. Large -scale data include genome -wide association studies (GWAS), single nucleotide 
polymorphisms (SNP) arrays, and genome sequence, transcriptomic, epigenomic, and gene expression data.  
 
10.1.12  CONFLICT OF INTEREST POLICY  
The University of North Carolina at Chapel Hill recognizes that conflicts of interest will arise from the 
research enterprise, from technology transfer activities, and from the many facets of our investigators’ professional activities. UNC seeks to identify and manage these conflicting relationships, restricting activities where necessary, to preserve transparency, independent decision -making, protection of 
research participants, and integrity of the educational experience. UNC’s Conflict of Interest Office    will 
have oversight over this study. 
 
10.2 ABBREVIATIONS  
 
ADE Antibody Mediated Enhancement of Infection  
AE Adverse Event  
ANCOVA  Analysis of Covariance  
ARDS  Acute Respiratory Disease Syndrome  
ALT Alanine Transaminase  
AST Aspartate Aminotransferase  
BDC  Blood Donation Center  
BUN  Blood Urea Nitrogen  
CB Campus Box  
CBC Complete Blood Count  
CCP Convalescent COVID -19 Plasma  
CDC Center s for Disease Control  and Prevention  
CFR Code of Federal Regulations  
CLIA  Clinical Laboratory Improvement Amendments  
CMP  Clinical Monitoring Plan  
COC  Certificate of Confidentiality  
CONSORT  Consolidated Standards of Reporting Trials  
COVID -19 SARS -CoV-2 
CRF Case Report Form  
CT CAT scan  
CTCAE  Common Terminology Criteria for Adverse Events  
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   39 CTRC  Clinical and Translational Research Center  
DCC Data Coordinating Center  
DHHS  Department of Health and Human Services  
DRE Disease -Related Event  
DSMB  Data and Safety Monitoring Board  
EC Ethics Committee  
ECG/EKG  Electrocardiogram  
ECMO  Extracorporeal Membrane Oxygenation  
eCRF  Electronic Case Report Forms  
EMR  Electronic Medical Record  
EOS End of Study  
FDA Food and Drug Administration  
FDAAA  Food and Drug Administration Amendments Act of 2007  
FFP Fresh Frozen Plasma  
FFR Federal Financial Report  
GCP Good Clinical Practice  
GLP Good Laboratory Practices  
GMP  Good Manufacturing Practices  
GWAS  Genome -Wide Association Studies  
HIPAA  Health Insurance Portability and Accountability Act  
IB Investigator’s Brochure  
ICH International Conference on Harmonisation  
ICMJE  International Committee of Medical Journal Editors  
ICU Intensive Care Unit  
IDE Investigational Device Exemption  
IgA Immunoglobulin A  
IgG Immunoglobulin G  
IgM Immunoglobulin M  
IGHID  Institute for Global Health and Infectious Disease s  
IND Investigational New Drug Application  
INR International Normalized Ratio 
IRB Institutional Review Board  
ISBT  International Society of Blood Transfusions  
ISM Independent Safety Monitor  
ISO International Organization for Standardization  
ITT Intention -To-Treat  
IV Intravenous  
IVIg Intravenous Immune Globulin  
LDH Lactate Dehydrogenase  
LSMEANS  Least -Squares Means  
LTFU  Lost to Follow -up 
MedDRA  Medical Dictionary for Regulatory Activities  
MOP  Manual of Procedures  
MSDS  Material Safety Data Sheet  
NCI National Cancer Institute  
NCT National Clinical Trial  
NC TraCS  North Carolina Translational and Clinical Sciences Institute  
NEWS  National Early Warning Score  
NIH  National Institutes of Health  
NIH IC  NIH Institute or Center  
NIV  Non -Invasive Ventilation  
NSI New Safety Information  
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   40 OHRP  Office for Human Research Protections  
OR Odds Ratio 
PCR Polymerase Chain Reaction  
PI Principal Investigator  
PID  Participant Identification  
PO Proportional Odds  
PT Prothrombin Time  
PTT Partial Thromboplastin Time 
QA Quality Assurance  
QC Quality Control  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SMC  Safety Monitoring Committee  
SNP Single Nucleotide Polymorphisms  
SOA  Schedule of Activities  
SOC Standard of Care 
SOFA  Sequential Organ Failure Assessment Score  
SOP Standard Operating Procedure  
TACO  Transfusion Associated Circulatory Overload  
TRALI  Transfusion -Related Acute Lung Injury  
UNC  University of North Carolina  
US United States  
WHO  World Health Organization  
 
10.3 PROTOCOL AMENDMENT HISTORY  
The table below is intended to capture changes of IRB -approved versions of the protocol, including a description of 
the change and rationale. A Summary of Changes table for the current amendment is located in the Protocol Title 
Page.  
 
Version  Date  Descrip tion of Change  Brief Rationale  
2.0 24 Aug 2020  Modification to reflect changes in 
knowledge about disease entity 
and changes in care.   
2.0 24 Aug 2020  Modification to Schedule of 
Activities  (SOA)  Removed procedures and clinical 
assessments from screening visit 
to reduce unnecessary procedure s 
until study eligibility confirmed  
2.0 24 Aug 2020  Modified text in protocol to clarify 
procedures related to sample collections and clinical 
assessments for study 
participation.  Simplif ied and clarif iedprotocol 
procedures to :  
- identify hospital SOC 
procedures as separate from 
study procedures  
- clarify processes to allow modified participant contact 
and reduce unnecessary 
procedures  
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   41 2.0  24 Aug 2020  Modification to the inclusion and 
exclusion  criteria (section s 5.1 and 
5.2) to clearly define exclusionary 
criteria, especially with the initiating of other therapeutics for COVID -19 To account for the development 
of new monoclonal antibody and T cells therapeutics since protocol inception.  
To d efine what numbers of days 
that are relevant for study 
exclusion . 
3.0  30 Oct 2020  Section 1.3 Schedule of Activities 
(SOA) and Section 8.1  Efficacy 
Assessments:   
Clarified text and collection time points related to samples. More 
clearly defined and identified 
study -required visits and samples 
from those that are optional.  The former protocol version 2.0 
did not accurately identify the optional visits and samples, leading to a lot of confusion on which samples to collect and 
when.  
3.0  30 Oct 2020  Section s 1.3 and 8.1 :  
Removal of Targeted Physical 
Exams  The longitudinal visits are for 
sample testing. No clinical data required for study analysis.  
3.0  30 Oct 2020  Section 1.3  SOA :  
Removed urine from sample collections.  Testing of these samples 
determined to be less important than the other epithelial lining 
samples.  
3.0  30 Oct 2020  Section 1.3 SOA :  
Changed pregnancy testing to include all women who are less than 60 years of age  Since many participants are not 
clinically stable or able to answer questions, and medical records may not be available to support child bearing potential, pregnancy testing on all women < 60 years of age eliminated the need  to ask  
family members personal health 
information  on the participant .  
3.0  30 Oct 2020  Section 8.1  Efficacy Assessments:   
Broadened terms to avoid requiring testing (NP swab) that many participants do not want to 
have again.  Many participants uninterested in 
having any additional NP sw ab 
samples taken if unnecessary.  
3.0  30 Oct 2020  Section 8.3  Adverse Events and 
Serious Adverse Events:  
Clarification of AE reporting Although intent of protocol 
remains unchanged, the language 
for grading was clarified due to 
the many confounding AEs that occur solely due to the severity of the illness and not related or 
associated with the CCP 
transfusions .  
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   42 3.1  18 Nov 202 0 Allow for continued enrollment up 
to 150 participants. Primary 
analysis will start when 56 partic ipants are enrolled with 
receipt of CCP.  While the initial analysis of n=56 is 
ongoing, we will continue to enroll 
given the potential for benefit, and for  expanded  analysis . 
Following initial analysis we will 
make a conclusion and close the study, or offer an analysis plan for additional enrolle es up to 150 .  
    
    
    
    
11 REFERENCES  
1. Hung I, To K, Lee, K- L, Chan K, Yan W -W, et al . 2011. Convalescent plasma treatment reduced mortality 
in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 52 (4):447– 456.  
2. Beigel J, Tebas P, Elie-Turenne M -C, Bajwa E, Bell TE, et al. 2017. Immune plasma for the treatment of 
severe influenza: An Open -label, multicenter, phase 2, randomized Study.  Lancet Respir Med. 5(6): 500-
511 
3. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, 
Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L.  2020. 
Treatment of 5 Critically Ill Patients With COVID -19 With Convalescent Plasma. JAMA  
doi:10.1001/jama.2020.47 
4. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y, Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, 
Shi Z, Chen S, Chen Z, Zhang X, Yang X.  2020. Effectiveness of convalescent plasma therapy in severe 
COVID -19 patients. Proceedings of the National Academy of Sciences  
doi:10.1073/pnas.2004168117:202004168.  
5. Bhatraju  P, Ghassemieh B, Nichols M, Kim R, et al.  2020 . Covid -19 in critically ill patients in the Seattle 
region —case series. NEJM. doi : 10.1056/NEJMoa2004500  
6. Sheahan T, Sims A, Graham R, Menachery V, et al. 2017. Broad -spectrum antiviral GS- 5734 inhibits both 
epidemic and zoonotic coronaviruses. Sci Trans Med.  9(396): eaal3653 
7. Falsey, A.R., Koval, C., DeVincenzo, J.P., and Walsh, E.E. 2017. "Compassionate use experience with high -
titer respiratory syncytical virus (RSV) immunoglobulin in RSV -infected immunocompr omised persons." 
Transplant Infectious Disease 19:e12657.  
8. Lejeune, A., Martin, L., Santibanez, S., et al. 2017. "Postexposure prophylaxis with intravenous 
immunoglobulin G prevents infants from getting measles." Acta Paediatrica 106:174 -177.  
9. Raanani, P., Gafter- Gvili, A., Paul, M., et al. 2009. "Immunoglobulin prophylaxis in chronic lymphocytic 
leukemia and multiple myeloma: systematic review and meta- analysis." Leukemia & Lymphoma 50:764-
772.  
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   43 10. Cheng, Y., Wong, R., Soo, Y., et al. 2005. "Use of convalescent plasma therapy in SARS patients in Hong 
Kong." European Journal of Clinical Microbiology & Infectious Diseases 24:44 -46. 
11. Zhang JS, Chen JT, Liu YX, Zhang ZS, Gao H, Liu Y, Wang X, Ning Y, Liu YF, Gao Q, Xu JG, Qin C, Dong XP, 
Yin WD.  2005. A serological survey on neutralizing antibody titer of SARS convalescent sera. J Med Virol  
77:147- 50 
12. Sahr F, Ansumana R, Massaquoi TA, Idriss BR, Sesay FR, Lamin JM, Baker S, Nicol S, Conton B, Johnson W, 
Abiri OT, Kargbo O, Kamara P, Goba A, Russell JB, Gev ao SM. 2017. Evaluation of convalescent whole 
blood for treating Ebola Virus Disease in Freetown, Sierra Leone. J Infect  74:302 -309 
13. Mair- Jenkins, J., Saavedra -Campos, M., Baillie, J.K., et al. 2015. "The Effectiveness of Convalescent 
Plasma and Hyperimmune  Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of 
Viral Etiology: A Systematic Review and Exploratory Meta- analysis." The Journal of Infectious Diseases 
211:80- 90. 
14. Mehta, P. McAuley, D., Brown, M., et al. 2020. "COVID -19: consider  cytokine storm syndromes and 
immunosuppression." The Lancet 395:1033 -1034.  
15. Casadevall A, Pirofski L.  2003. The damage -response framework of microbial pathogenesis. Nat Rev 
Microbiol 1:17 -24. 
16. Wölfel R,  Corman V, Guggemos W, Seilmaier M, Zange S, et al. 2020. Virological assessment of hospitalized patients with COVID -2019. Nature . https://doi.org/10.1038/s41586 -020-2196 -x 
17. To K K- W, Tsang O, Leung W -S, Tam A, et al. 2020. Temporal profiles of viral load in posterior 
oropharyngeal saliva samples and serum antibody responses during infection by SARS -CoV-2: an 
observational cohort study. The Lancet Infectious Diseases. doi: 10. 1016/S1473 -3099(20)30196 -1 
18. Liu Y, Yan L -M, Wan L, Xiang T -X, et al . 2020. Viral dynamics in mild and severe cases of COVDI -19. Lancet 
Infectious Diseases . doi.org/10.1016/S1473- 3099(20)30232 -2  
19. He Z, Dong Q, Zhuang H, Song S. 2004. Kinetics of Severe Acute Respiratory Syndrome (SARS) 
Coronavirus -Specific Antibodies in 271 Laboratory -Confirmed Cases of SARS. Clin Diagn Lab Immunol . 
11(4): 792- 794.  
20. Halstead, S., Mahalingam, S., Marovich, M., et al. 2010. Intrinsic antibody -dependent enhancement of 
microbial infection in macrophages: disease regulation by immune complexes. Lancet Infectious 
Diseases 10:712- 22. 
21. Katzelnick, L.C., Gresh, L., Halloran, M.E., et al. 2017. "Antibody -dependent enhancement of severe 
dengue disease in humans." Science 358:929 -932.  
22. Vennema, H., de Groot, R.J., Harbour, D.A., et al. 1990. "Early death after feline infectious peritonitis 
virus challenge due to recombinant vaccinia virus immunization." Journal of Virology 64:1407 - 1409.  
23. Wan, Y., Shang, J., Sun, S., et al. 2020. "Molecular Mechanism for Antibody -Dependent Enhancement of 
Coronavirus Entry." Journal of Virology 94:e02015- 19. 
24. Beigel J, Aga E, Elie -Turenne M -C, Cho J, Tebas P, et al. et al. 2019. Anti- influenza immune plasma for the 
treatment of patients with severe influenza A: a randomised, double -blind, phase 3 trial. The Lancet 
Respiratory Medicine . 7(11):941 -950.  
25. Niewiesk S, 2014. Maternal Antibodies: Clinical Significance, Mechanism of Interference with Immune 
Responses, and Possible Vaccination Strategies . Front Immunol . 5:446. doi:  10.3389/fimmu.2014.00446 
26. van GJ, Edwards T, de L, X, Semple MG, Gallian P, Baize S, Horby PW, Raoul H, Magassouba N, Antierens A, Lomas C, Faye O, Sall AA, Fransen K, Buyze J, Ravinetto R, Tiberghien P, Claeys Y, De CM, Lynen L, Bah 
IGHID 12021 - A Randomized Study Comparing the Efficacy and Safety of CCP Hospitalized Patients  Version 3.1  
                      18 November 2020 
UNC IND Convalescent COVID -19 Plasma Clinical Trial   44 EI, Smith PG, Delamou A, De WA, Haba N.  2016. Evaluation of Convalescent Plasma for Ebola Virus 
Disease in Guinea. N Engl J Med 374:33 -42. 
27. Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, Chen Q, Zhang L, Zhong Q, Zhang X, Zou Y, Zhang S.  
2020. Treatment with convalescent plasma for critically ill patients with SARS -CoV-2 infection. Chest 
doi:10.1016/j.chest.202 0.03.039.  
28. Reference Investigational COVID -19 Convalescent Plasma Guidance for Industry U.S. Department of 
Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research  
May  2020 Updated May 1, 2020  
29. Zhou F, Yu T, Du R, F an G, Liu Y, Liu Z et al. 2020; Clinical course and risk factors for mortality of adult 
inpatients with COVID -19 in Wuhan, China: a retrospective cohort study. Lancet  39: 1054 –62  